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Introduction
In Europe and the United States of America, prostate cancer (PCa) is the most 
common diagnosed form of cancer among males.1 Approximately, one out of six 
men will be diagnosed with the disease. Luckily, the majority of men with PCa will 
not die from the disease, instead, they die with the disease.2 The reason is that 
most men with prostate cancer have low-risk localized PCa. As these low-grade, 
small-volume and organ-confined PCa lesions are not likely to influence a patient 
his well-being nor his morbidity, these lesions are often referred to as clinically 
insignificant PCa. Against this, clinically significant PCa (csPCa) is supposed to 
affect a man his life.3 Therefore, the challenge in PCa diagnostics is to accurately 
identify and detect csPCa without detecting clinically insignificant PCa lesions.
 The current standard to diagnose PCa is the pathological examination of 
prostate tissue obtained with transrectal ultrasound (TRUS) guided biopsies after 
PSA testing.4 TRUS biopsy is performed in men with raised prostate specific antigen 
(PSA) blood levels or in men with an abnormal digital rectal examination (DRE). 
Systematically, 10-12 biopsy cores are obtained as prostate cancer is often not 
visible on ultrasound.5,6 Unfortunately, with the combination of PSA, DRE and TRUS 
we currently have an inadequate diagnostic work-up for csPCa. A first drawback of 
TRUS guided biopsy is the over-diagnosis of clinically insignificant PCa. Contrarily, 
the second drawback is the under-diagnosis of csPCa.7,8 Often, csPca is missed when 
using TRUS guided prostate biopsy. Other drawbacks are the underestimation of 
PCa aggressiveness, the risk of developing sepsis and the use of 10-12 biopsy cores, 
making it an unpleasant procedure.9 On the other hand, advantages of TRUS-guided 
biopsy are the low costs and the ease of use, making the technique readily available 
to implement.
multiparametric MRI
Since the introduction of multiparametric MRI (mpMRI) and MRI-guided prostate 
biopsy about a decade ago, there has been a paradigm shift in PCa diagnostics.10,11 
mpMRI is a combination of anatomical and functional MR images that together 
allow for an accurate assessment of the prostate. To depict the anatomy of the 
prostate, T2-weighted images are used. The most used functional MR images are 
diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCE).
T2-weighted imaging
T2-weighted imaging is the cornerstone of prostate mpMRI. Due to the high spatial 
resolution and soft tissue contrast, T2-weighted imaging is ideal for differentiating 
between the high-signal-intense peripheral zone (PZ) and the low-signal-intense 
transition zone (TZ) of the prostate. To increase the diagnostic accuracy of 
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MRI-targeted biopsy
To date, pathological confirmation of obtained biopsies is still standard to definitively 
confirm the diagnosis and to assess cancer aggressiveness. Using the detection 
and localizing ability of mpMRI, it has become possible to perform MRI-targeted 
biopsy rather than systematically sampling the prostate with TRUS-guided biopsy. 
Different ways to target suspected lesions are practiced. For example, direct in-bore 
MR guided biopsy (MRGB) and MRI-TRUS fusion guided biopsy (FGB). 
Direct in-bore MR-guided biopsy
Currently, the most commonly used MRGB device is a manually adjustable 
positioning device for needle guide positioning. A needle guide is inserted in the 
rectum of the patient. Based on the acquired MR images, the needle guide is 
manually positioned in the direction of the suspicious lesion. In order to manipulate 
the direction of the needle guide, the patient has to be withdrawn from the magnet 
bore and positioned inside the magnet bore again for imaging. Consequently, the 
physician repeatedly changes between the scanner room and control room to 
adjust the needle guided direction and interpret the MR images, respectively. 
Besides the fact that less biopsy cores are needed for diagnosis, this MRGB 
technique increases the csPCa detection rates in patients.11 However, MRGB is a 
time consuming and expensive diagnostic procedure.  
MRI-TRUS fusion
In FGB preprocedural achieved mpMRI images are fused with real-time TRUS images. 
This can be done software assisted or cognitively. In software assisted FGB, mpMRI 
data has to be loaded onto an ultrasound platform. Software registration combines 
the advantages of both mpMRI and TRUS by targeting the biopsy needle with 
real-time TRUS into a previously mpMRI selected lesion. The main difference 
between the different commercially available FGB platforms is the method of 
image registration being either rigid or elastic. In elastic image registration, the 
biopsy platforms tries to compensate for possible deformation of the prostate 
caused by the introduction of the ultrasound probe. Rigid image registration does 
not compensate for this prostate deformation. 
Current challenges
Nowadays, several routines are being practiced in the diagnostic work up of PCa. 
Though, there are still some questions to be answered. For example, mpMRI is 
increasingly being used to detect and localize PCa. Due to a sensitivity of 93% 
(95% CI, 88-96) and a negative predictive value of 89%, patients without suspicious 
lesions seen on mpMRI may safely avoid biopsy. Currently, it is not well established 
which proportion of men avoid such a biopsy in a daily clinical routine. Also, it is 
MRI for csPCa, T2-weighted images should be used along with functional imaging 
techniques.
Diffusion-weighted imaging
In diffusion-weighted imaging (DWI), the Brownian motion of water protons is 
displayed. Brownian motion is the absolute random motion of water molecules in 
unrestricted tissue. 
 DWI consists of two components: high b-value images and an apparent diffusion 
coefficient (ADC). As PCa is highly cellular, it thus restricts water movement which 
is characterized by a high signal intensity on high b-value images.12
 An ADC map is calculated from at least two b-values. An ADC map is an automated 
calculation process from the MR-scanner. In contrast to high b-value images, highly 
cellular tissue is reflected by a low signal intensity on the ADC map.
Dynamic contrast-enhanced imaging
Dynamic contrast-enhanced imaging (DCE) is an imaging technique representing 
the vascular properties of tissue. Repeatedly acquired fast T1-weighted sequences 
before, during and after intravenous administration of a gadolinium-based contrast 
agent are used in DCE. Dedicated software is needed for post-processing the obtained 
images. Usually, color maps are extracted from the images for a simple understanding 
by both radiologists and non-radiologists. The colors used on those maps reflect a 
specific hemodynamic parameter.13 Like other cancers, PCa is highly vascularized.
PI-RADS 
In 2012 Barentsz et al.14 published the clinical guidelines for mpMRI of the prostate of 
the European Society of Urogenital Radiology (ESUR). Along with these guidelines, 
the first version of the Prostate Imaging Reporting and Data System (PI-RADS) 
classification was introduced (PI-RADS v1). The introduction of PI-RADS v1 allowed 
radiologists to assess the prostate in a structured manner using a scoring system with 
predefined requirements that a lesion must satisfy in order to be given a certain 
level of suspicion for being PCa. However, experience revealed some limitations 
and therefore there was a need for a new version (PI-RADS v2).15 Like version 1, 
PI-RADS v2 is based on a classification ranging from 1 to 5. Lesions are classified 
based on their appearance on mpMRI. The score predict its chance of being csPCa. 
The chance of being csPCa, for example, is highly likely in case of a PI-RADS 5 lesion, 
whereas the chance is likely at PI-RADS 4 and equivocal in PI-RADS 3 lesions.
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As different biopsy strategies are being practiced nowadays, we evaluated which 
prostate biopsy technique (systematic TRUS, MRGB or FGB) is most cost-effective. 
This cost-effectiveness comparison is described in Chapter 7.
Finally, in Chapter 8 the main findings of this thesis are discussed.
 
not well clarified what proportion of csPCa is detected in mpMRI lesions which are 
suspicious for harboring csPCa.
 Since we are able to localize csPCa, targeted biopsy is used for obtaining tissue 
for histopathological evaluation. As shown above, there are different ways to 
target such an mpMRI suspicious lesion. At this moment, it is unclear which 
targeted biopsy approach is most accurate and most cost-effective. In various 
ways, these raised questions will be tried to be answered.   
Aim and outline of this thesis
The aim of this thesis is to evaluate the role of mpMRI and MRI-targeted prostate 
biopsy in men with a clinical suspicion of PCa. As different biopsy approaches are 
being practiced, this thesis further aims to evaluate the role of these different 
biopsy techniques, especially MRGB and FGB. 
Nowadays, mpMRI is increasingly being used to detect and localize PCa. Because of 
its high sensitivity and negative predictive value, a proportion of patients, those 
without suspicious lesions, can safely avoid biopsy. In Chapter 2 we investigated 
that proportion. 
Chapter 3 provides an overview of the detection of (cs)PCa in lesions scored 
PI-RADS 3, 4 or 5. We evaluated the pathology results after the biopsy of lesions 
which are classified equivocal, likely or highly likely to be clinically significant on 
mpMRI. Further, we evaluated in this chapter the ability of the PSA blood level 
divided by the volume of the prostate (PSA density) to predict csPCa in lesions 
which are equivocal to be csPCa. 
Next, in Chapter 4, a retrospective head-to-head comparison between MRGB and 
FGB is presented. We compared the detection rates for both csPCa and any PCa 
between both MRI-targeted biopsy techniques.
In Chapter 5 we evaluated the yield of repeating an MRGB in a suspicious lesion in 
men who have had a previously MRGB which was negative for PCa in that same lesion.
Currently, the most used MRI-targeted prostate biopsy technique is FGB. Different 
manufacturers are offering software assisted FGB. As explained earlier, the main 
difference between the systems is in the way of image registration being either 
rigid or elastic. Therefore, the aim of Chapter 6  was to compare rigid and elastic 
image registration and to compare FGB with 10-12 core systematic TRUS biopsy.  
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Experience in 4259 men to avoid 
prostate biopsy by using multiparametric 
MRI and PI-RADS at an expert centre
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Introduction
The current standard of care in men suspected of having prostate cancer (PCa) is a 
systematic 10-12 core transrectal ultrasound (TRUS) biopsy.1 However, this technique 
is limited as clinically significant (cs)PCa is often missed, clinically insignificant 
cancers are unnecessarily detected and men undergo biopsy while they do not 
have PCa. In the past few years, evidence accumulated to reduce the above mentioned 
limitations of TRUS biopsy by using multiparametric (mp)MRI. As a consequence, 
mpMRI is now increasingly being used to detect and localize csPCa. The opportunity 
to adequately localize csPCa allows mpMRI to direct the biopsy needle towards 
a mpMRI suspicious lesion. By using mpMRI and subsequent MRI targeted biopsy, 
in a proportion of men biopsy may be avoided. Also, mpMRI reduces the over- 
diagnosis of clinically insignificant PCa.2,3 Recently, the PROMIS trial reported 
that 27% of patients may safely avoid biopsy by using mpMRI as triage test.4 
In addition, the PRECISION trial reported similar results.5 It has been shown that 
in a well performed mpMRI, patients with negative findings can safely avoid biopsy 
because of its high sensitivity and negative predictive value (NPV).4,6,7 However, 
recent publications showed differences in biopsy thresholds. For example, in our 
institution men with lesions classified 1 or 2 according to the Prostate Imaging 
Reporting And Data System version 2 (PI-RADS)8 and a low clinical suspicion of 
csPCa do not undergo biopsy, while in other institutes men with lesions classified 
PI-RADS ≥ 2 undergo biopsy.9-12 Moreover, recently, the concept of using PSA 
density (PSAD) in combination with PI-RADS is also being suggested as additional 
risk tool for csPCa, that can be used to select men who may avoid targeted biopsy 
in PI-RADS 3 lesions.11,13,14
 Current results regarding patients avoiding biopsy are largely based on prospective 
trials in which often double reading is performed or in which multiple, often less 
experienced, institutions are involved, and not always using 3T MR-scanners. Also, 
there is limited literature regarding follow-up in patients with negative mpMRI 
findings.  
 Therefore, the purpose of our study was to determine the percentage of men 
who avoided prostate biopsy by using mpMRI in an expert centre and to assess the 
number of clinically significant (cs)PCa detected during follow-up in these patients.
Abstract
Background The limitations of systematic transrectal ultrasound (TRUS) biopsy 
resulted in increased use of multiparametric (mp)MRI for the diagnostic work up 
of males suspected of having prostate cancer (PCa). The proportion of males avoiding 
prostate biopsy in an expert centre is not yet established.
Objective The aim of our study was to determine the proportion of males avoiding 
biopsy because of negative mpMRI findings in an prostate MRI experienced centre 
and to determine the amount of clinically significant (cs)PCa detected during 
follow up in those patients. 
Design Prospectively collected data of patients having mpMRI of the prostate in 
our institution between January 2012 and December 2017 were collected. We included 
males suspected to have prostate cancer with either a history of negative TRUS 
biopsy or those who were biopsy naïve. Lesions were classified according to Prostate 
Imaging Reporting And Data System (PI-RADS) version 1 and 2 by one of our eight 
radiologists, with varying degree of experience. Institutional review board approval 
was obtained with a waiver of informed consent.    
Outcome Measurements and Statistical Analysis  Primary outcome was the 
proportion of patients with a negative mpMRI, defined as an index lesion classified 
PI-RADS ≤ 2. Descriptive statistics were used. Histopathologic follow up until 
26 March 2018 was collected by searching the Dutch Pathology Registry (PALGA). 
Gleason score ≥ 3+4 was considered clinically significant (cs)PCa.   
Results and limitations  A total of 4259 men were included. The median age was 
65 years (interquartile range [IQR], 60-70) and median PSA was 8.5 ng/ml (IQR, 
6.0-13.0). Patients had a history of prior negative TRUS biopsy in 47.9 % (n = 2039) 
and were biopsy naïve in 52.1% (n = 2220). In 53.6% (2281/4259) an index lesion 
was classified PI-RADS ≤ 2. Deciding not to biopsy lesions classified PI-RADS 3 with 
a PSA density below 0.15 ng/ml/ml would result in an additional 5.8% (total 
proportion 59.4%) of patients avoiding biopsy. 
 In 0.4% (9/2281) of the patients with a PI-RADS 1 or 2 classification, csPCa was 
detected after a median period of 29 months (IQR, 16-49).
Conclusions  More than half of patients having mpMRI of the prostate avoided 
biopsy because of negative findings on mpMRI. Follow up rarely results in csPCa. 
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Results
We included 4259 patients. These patients had a history of prior negative TRUS 
biopsy in 47.9 % (n = 2039) and were biopsy naïve in 52.1% (n = 2220). The median 
age was 65 years (interquartile range [IQR], 60-70) and median PSA was 8.5 ng/ml 
(IQR, 6.0-13.0). An overview of patient characteristics is listed in Table 1. 
PI-RADS
Overall, in 53.6% (2281/4259) the index lesion was classified PI-RADS ≤ 2. Thus, 
46.4% (1978/4259) needed targeted biopsy because of a PI-RADS 3-5 index lesion 
(Figure 1). Within the patients with prior negative TRUS biopsy and within the 
biopsy naïve patients, 52.7% (1075/2039) and 54.3% (1206/2220) were classified 
PI-RADS ≤ 2 respectively. In the entire cohort, in 11.7% (499/4259) the radiologists 
classified a lesion PI-RADS 3, which was 14.5% (296/2039) and 9.1% (203/2220) in 
patients with prior negative TRUS biopsy and in biopsy naïve patients respectively. 
Table 2 shows the distribution of PI-RADS of the entire cohort.
 Differences in patient characteristics between the radiologists are presented 
in supplementary 1. The proportion of lesions classified PI-RADS ≤ 2 varied from 
42.9% (176/410, radiologist 7) to 64.2% (174/271, radiologist 6). The difference in 
distribution over the years was even smaller, as is shown in Figure 2. 
Material and Methods
Prospectively acquired data from consecutive patients having their first mpMRI of 
the prostate in our institution between January 2012 and December 2017 were 
retrospectively collected from our Picture Archiving and Communication System 
(PACS). Institutional review board approval was obtained with a waiver of informed 
consent. Included patients had a clinical suspicion for PCa with either a history of 
negative TRUS biopsy or were biopsy naïve. Patients with biopsy proven PCa and 
patients with a prior mpMRI of the prostate were excluded from this study. Included 
patients did not participate in trials within our institution.
Multiparametric MRI
All mpMRI images were obtained using a 3.0 T MR scanner (Skyra; Siemens) with a 
pelvic phased-array coil. Triplanar T2-weighted images, axial diffusion weighted 
images and axial dynamic contrast enhancement series were obtained according to 
the PI-RADS v1 or v2 criteria.8,15 Since 2012 mpMRI parameters are slightly 
adjusted. However, it met PI-RADS criteria. Images were classified according to the 
risk assessment either from PIRADS v1 or v2 by one of eight radiologists, who were 
in-house trained in prostate MR reading (2-20 years of experience). For this study, 
only the index lesions were used, as this lesion determined whether biopsy was 
needed. Most recent PSA prior to the mpMRI was collected. Next to the PI-RADS 
classification, radiologists reported the MRI-PSA density (mPSAD), which is calculated 
by dividing PSA by the prostate volume on mpMRI. 
Data analysis
Descriptive statistics were used for both patient and mpMRI characteristics. 
The main objective of this study was to determine the amount of men who avoided 
biopsy. Subgroup analysis was performed for patients with a PI-RADS 3 classification 
to further evaluate the proportion of patients avoiding biopsy by the addition of 
different mPSAD threshold next to the PI-RADS classification. Analyses were 
performed using SPSS software (version 22; IBM). Follow-up until 26 March 2018 
was collected using the nationwide network and registry of histo- and cytopathology 
in the Netherlands (PALGA).16 The follow-up data consisted of histopathology 
obtained by either TRUS or targeted biopsy. Gleason score ≥ 3+4 was considered 
clinically significant (cs)PCa.
Table 1  Patient characteristics
Age, yr, median (IQR) 65 (60-70)
Prior TRUS biopsy, n (%) 2039 (47.9)
Biopsy naïve, n (%) 2220 (52.1)
PSA (ng/ml), median (IQR) 8.5 (6.0-13.0)
Prostate volume (ml), median (IQR) 64.0 (46.0-92.0)
PSAD (ng/ml/ml), median (IQR) 0.13 (0.09-0.20)
Year in which mpMRI is performed, n (%)
2012 665 (15.6)
2013 573 (13.5)
2014 521 (12.2)
2015 808 (19.0)
2016 785 (18.4)
2017 907 (21.3)
IQR = inter quartile range; mpMRI = multiparametric MRI; PI-RADS = Prostate Imaging Reporting And 
Data System; PSA = prostate specific antigen; PSAD = PSA density; TRUS = Transrectal ultrasound
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Follow-up
After a median of 31 months (IQR, 18-52), 3.2% (74/2281) of the patients with 
PI-RADS ≤ 2 had a follow-up examination of the prostate reported in the nationwide 
network and registry of histo- and cytopathology in the Netherlands. For PI-RADS 
3 this was 28.9% (144/499).
 In these 74 patients with PI-RADS ≤ 2, follow-up was acquired after a median 
of 9 months (IQR, 2-23). Follow-up consisted of TRUS biopsy in 42 patients and 
targeted biopsy in 32 patients. Within the entire cohort of patients with PI-RADS 
1 and 2, PCa was detected in 1.1% (25/2281) and csPca was detected in 0.4% 
(8/2281). Specified for the cohort of 74 patients with follow-up, csPCa was detected 
in 10.8% (8/74). CsPCa was detected with TRUS biopsy and with targeted biopsy 
both 4 times.
In the 144 of the 499 patients with PI-RADS 3, follow-up was obtained after a 
median of 40 days (IQR, 25-114). TRUS biopsy was done in 9 patients and targeted 
biopsy in 135 patients. Follow-up was negative in 92 patients. Any PCa was detected 
in 52 patients, and csPCa was detected in 26 patients. CsPCa was solely detected 
with targeted biopsy.
PSA density in PI-RADS 3
In the entire cohort, 57.2% (2435/4259) of the patients had an index lesion 
classified PI-RADS ≤ 2 or PI-RADS 3 with a mPSAD below 0.12 ng/ml/ml, in these 
patients biopsy could have been avoided.11 This increases to 58.8% (2506/4259) if 
the threshold were to be shifted to a mPSAD of 0.15 ng/ml/ml in patients with a 
PI-RADS 3 index lesion. The distribution of mPSAD in the cohort of 499 patients 
with a PI-RADS 3 is specified in Table 3.
Figure 1  Distribution of PI-RADS scored in the entire cohort
Table 2  PI-RADS distribution of the entire cohort
PI-RADS n % Cu %
1 165 3.9 3.9
2 2116 49.7 53.6
3 499 11.7 65.3
4 656 15.4 80.7
5 823 19.3 100.0
Total 4259 100.0 100.0
Cu % = Cumulative percentage; PI-RADS = Prostate Imaging Reporting And Data System
Figure 2  Distribution of PI-RADS displayed per year
PI-RADS = Prostate Imaging Reporting And Data System.
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Discussion
The primary finding of our study is that 53.6% of patients had a negative mpMRI 
(PI-RADS ≤ 2) and avoided biopsy in our institution. An additional 5.2% could 
avoid biopsy in PI-RADS 3 lesions with a mPSAD below 0.15 ng/ml/ml. Our follow-up 
data shows that a negative mpMRI is reassuring to patients and urologists as in 
only 3.2% further TRUS or targeted biopsy was obtained after a median of 31 months. 
A clinically significant PCa was found only in 0.4% for PI-RADS 1-2 and 0.7% for 
PI-RADS 1-2 plus PI-RADS 3 with a mPSAD <0.12ng/ml/ml.    
Our results are the first to report on such a large cohort of patients with a clinical 
suspicion of csPCa having an mpMRI in an clinical setting atan expert setting. 
The finding that in clinical practice more than 50% of patients who have a negative 
mpMIR may avoid biopsy, underlines the importance of mpMRI in the diagnostic 
work up of csPCa. By avoiding additional biopsy, costs and post-biopsy complications 
can be reduced.17-19       
 Compared to the findings of the PROMIS trial as well as the findings of the 
PRECISION trial, our number of patients who could avoid biopsy are approximately 
twice as high.4,5 Next to these trials, also other groups presented results remarkably 
There was follow-up in 49 of the 154 patients with a mPSAD below 0.12 ng/ml/ml. 
Eight of them had csPCa (0.4%). There was follow-up in 63 of 225 patients with a 
mPSAD below 0.15 ng/ml/ml. In 13 of these patients csPCa was found.
 A csPCa was found in 0.7% (16/2435) for PI-RADS 1-2 plus PI-RADS 3 with a 
mPSAD <0.12ng/ml/ml and in 0.8% (21/2506) for PI-RADS 1-2 plus PI-RADS 3 with 
a mPSAD <0.15ng/ml/ml. 
Supplementary table 1  Patient characteristics per radiologist
Characteristics Radiologist
1 2 3 4 5 6 7 8
Years of experience 20 12 5 5 5 5 10 2
Total mpMRI studies, n (%) 820 (19.3) 567 (13.3) 1128 (26.5) 724 (17.0) 289 (6.8) 271 (6.4) 410 (9.6) 50 (1.2)
Age, median (IQR) 65 (60- 69) 65 (60-70) 66 ( 60-70) 65 (60-70) 66 (61-70) 66 (60-70) 65 (60-69) 64 (59-69)
PSA, median (IQR) 9.0 (6.4-14.0) 9.1 (6.2-15.0) 7.5 (5.4-11.0) 8.9 (6.3-13.1) 8.7 (6.2-12.0) 6.8 (5.0-9.0) 10.0 (7.0-16.0) 11.5 (7.8-16.3)
Prior TRUS biopsy,  n (%) 483 (58.9) 291 (51.3) 395 (35.0) 368 (50.8) 146 (50.5) 53 (19.6) 266 (64.9) 36 (72.0)
Biosy naïve, n (%) 337 (41.1) 276  (48.7) 733 (65.0) 356 (49.2) 143 (49.5) 218 (80.4) 144 (35.1) 14 (28.0)
PSA density, median (IQR) 0.14 (0.09-0.21) 0.14 (0.09-0.22) 0.11 (0.08-0.16) 0.14 (0.09-0.23) 0.12 (0.09-0.20) 0.10 (0.07-0.15) 0.16 (0.11-0.26) 0.22 (0.13-0.32)
PI-RADS, n (%)
1 60 (7.3) 19 (3.4) 72 (6.4) 5 (0.7) 3 (1.0) 2 (0.7) 1 (0.2) 3 (6.0)
2 377 (46.0) 273 (48.1) 584 (51.8) 387 (53.5) 127 (43.9) 172 (63.5) 175 (42.7) 21 (42.0)
3 108 (13.2) 66 (11.6) 87 (7.7) 97 (13.4) 47 (16.3) 6 (2.2) 79 (19.3) 9 (18.0)
4 94 (11.5) 114 (20.1) 183 (16.2) 104 (14.4) 55 (19.0) 49 (18.1) 49 (12.0) 8 (16.0)
5 181 (22.1) 95 (16.8) 202 (17.9) 131 (18.1) 57 (19.7) 42 (15.5) 106 (25.9) 9 (18.0)
IQR = inter quartile range; mpMRI = multiparametric MRI; PI-RADS = Prostate Imaging Reporting And 
Data System; PSA = prostate specific antigen; PSAD = PSA density; TRUS = Transrectal ultrasound
Table 3  Distribution of PSAD in 499 patients with PI-RADS 3
PSAD (ng/ml/ml) n (499) % Cu %
≤ 0.1 123 24.6 24.6
0.11 31 6.2 30.9
0.12 21 4.2 35.1
0.13 29 5.8 40.9
0.14 21 4.2 45.1
0.15 22 4.4 49.5
≥0.16 252 50.5 100
Cu % = Cumulative percentage ; PI-RADS = Prostate Imaging Reporting And Data System; PSAD = Prostate 
Specific Antigen Density
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included in this paper. Therefore, follow-up was only available in a small amount 
of included patients. However, PALGA stores every pathology outcome in our 
country. As a consequence, in none of the patients without follow-up, there was 
PCa detected anywhere in the Netherlands. Therefore, with a median follow-up of 
31 months, it is not likely that highly aggressive PCa’s will be missed in patients 
with PI-RADS 1-2.
 Furthermore, several other studies have already investigated the NPV of 
mpMRI and concluded that patients with negative mpMRI results may safely avoid 
prostate biopsy.23-26 In a previous study we already reported biopsy outcome in 
patients with PI-RADS ≥ 3.11 
 As our study aimed to address the question which proportion of patients may 
avoid biopsy based on the current practice, the lack of direct pathological 
confirmation does not influence our conclusion.
 A second limitation is that results presented in this paper may be hard to 
extrapolate and only be applicable for a highly experienced prostate mpMRI center 
and could not be generalized as our institution is very experienced in acquisition 
and reading of mpMRI images. Due to weekly multidisciplinary biopsy meetings 
where pathology, MRI and targeted biopsy are discussed we established a steep 
learning curve. An advantage is that we demonstrated the potential of mpMRI if 
assessed by well-trained radiologists due to regular pathology feedback. 
Conclusions
In our large patient cohort (4259), mpMRI was classified negative of having csPCa 
in more than half of patients (53.6%). As a consequence, they may safely avoid 
biopsy and the subsequent inconveniences, risks and costs associated. Furthermore, 
a negative mpMRI is reassuring to patients and urologists as in only a few percent 
(3.2%) further TRUS or targeted biopsy was required, and csPCa’s (0.4%) were detected. 
differing from the results presented in this paper. In those studies, the cohort 
classified PI-RADS 1-2 varied from 11% to 38%.12,20-22 An explanation is that 
PI-RADS may be applied conservatively in the afore mentioned studies with a 
prospective study design, so as not to miss any significant tumors. This may 
introduce a bias, which is not present in the routinely scored exams of this 
retrospective study. Furthermore, our institution is very experienced in prostate 
MRI reading, which is reflected in the low number of patients classified PI-RADS 3 
(12%). This is low, for example, compared to the PROMIS trial (28%) or the 
PRECISION trial (20%). A PI-RADS 3 classification implies an uncertainty either 
due to the quality of the images or to the expertise of the radiologist or due to the 
patient population.
 Another explanation may be that a part of our patients with a PI-RADS 1 or 2 was 
false negative. However, our follow-up demonstrates that csPCa was rarely detected 
in patients with a negative mpMRI (0.4%). Therefore, it is unlikely that this is the 
explanation for the relatively large proportion of patients with PI-RADS ≤ 2. 
 In the recently published PRECISION trial, Kasivisvanathan et al. raised their 
concerns about men with negative results on mpMRI who do not undergo biopsy.5 
They referred to the PROMIS trial that showed that men with negative mpMRI 
findings have a low risk of csPCa (5%). In addition, the PRECISION trial demonstrated 
that negative mpMRI findings were more reassuring for patients and urologists 
than a negative result on TRUS biopsy. Our results confirm these findings by 
demonstrating that in a daily clinical setting only 3.2% of men with negative 
mpMRI findings requests additional TRUS or targeted biopsy and in only 0.4% 
csPCa was detected. In patients with equivocal findings (PI-RADS 3), a much larger 
group requests additional targeted biopsy (28.9%).     
 The most important strength of our study, is the large cohort of patients 
having a PI-RADS standardized mpMRI acquisition and reporting at a prostate MR 
expert centre. As the first patients included in our study had an mpMRI in 2012 
already, we explored the differences in PI-RADS distribution over the years. We 
demonstrated that scoring distribution did not differ notably.
 Despite the afore mentioned strengths, there are also several limitations. 
First, there is a lack of direct pathological confirmation after negative mpMRI 
results. It would be ideal to have a gold standard, for example template biopsy 
mapping, in all these men with negative mpMRI findings to ensure there is no 
csPca. Of course, this is not possible in a daily clinical setting. Therefore, follow-up 
data was obtained from PALGA. PALGA is a nationwide network and registry of 
histo- and cytopathology in the Netherlands. In this database, every histo- and 
cytopathology obtained in our country is stored. As a consequence, presented 
follow-up only consists of pathology obtained by TRUS or targeted biopsy. Follow-up 
concerning digital rectal examination, PSA or other biomarkers and mpMRI is not 
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Introduction
The role of magnetic resonance imaging (MRI) in the detection and localization of 
prostate cancer (PCa) rose after the introduction of multiple functional MRI parameters 
that were added to anatomical MRI approximately a decade ago.1-3 Despite the high 
performance of this multiparametric (mp)MRI, systematic 10-12 core transrectal 
ultrasound (TRUS) guided prostate biopsy is still the standard used to detect PCa.4
 To improve the diagnostic quality of prostate mpMRI and to simplify and 
standardize radiology reports, the European Society of Urogenital Radiology 
introduced in 2012 the first version of the Prostate Imaging Reporting And Data 
System (PI-RADS v1).5 Very recently, a new version (PI-RADS v2) was introduced.6
Both version 1 and version 2 of PI-RADS are scoring systems based on a 5-point 
Likert scale. Following the imaging characteristics of a lesion on the different MRI 
parameters, an overall score is given to a lesion to predict its chance of being 
clinically significant (cs) PCa. The chance of being csPCa, for example, is highly 
likely in case a PI-RADS score of 5 is given whereas the chance is likely at a score 
of 4 and equivocal in PI-RADS 3 lesions.
 After a PI-RADS assessment category is assigned to a lesion, the lesion has to 
be biopsied on a targeted way to confirm the diagnosis. One way to target such a 
lesion is by performing direct in-bore MRI guided biopsy (MRGB).  
 Despite much research in PI-RADS classification and different prostate biopsy 
approaches, a broad evaluation of the implication of PI-RADS in large cohorts of 
patients who have undergone MRGB is not performed yet. Therefore, the main aim 
of our study is to outline MRI-guided biopsy findings in patients with differing 
levels of suspicion at mpMRI and to demonstrate follow up of patients with negative 
biopsy findings despite a positive mpMRI. Further we will examine the ability of 
prostate specific antigen density (PSAD) to predict biopsy outcome, the implication 
location has on PCa detection and the meaning of detecting lesions next to the 
index lesion.
 We will address those issues based on our MRGB results since 2012 in men with 
lesions classified PI-RADS 3, 4 and 5. 
Patients and Methods
This retrospective study with prospectively collected data was approved by our 
institutional review board with a waiver of written informed consent (2016-2739). 
Abstract
Background  The Prostate Imaging Reporting And Data System (PI-RADS) is the 
most commonly used scoring system in prostate MRI. One of the available techniques 
to target suspicious lesions  is direct in-bore MRI-guided biopsy (MRGB).
Objective  To report on the experience and results of MRGB in a large cohort of 
patients with lesions classified as equivocal (PI-RADS 3), likely (PI-RADS 4) or 
highly likely (PI-RADS 5) to be clinically significant (cs) prostate cancer (PCa).
Design, Setting and Participants   We retrospectively included 1057 patients having 
MRGB, between January 2012 and September 2016, of lesions classified PI-RADS 
≥ 3 on mpMRI. Biopsy-naïve patients, patients with prior negative systematic 
transrectal ultrasound-guided (TRUS) biopsy and patients in active surveillance 
were included.
Outcome Measurements and Statistical Analysis  The primary outcome measurement 
is the detection rate of (cs)PCa. Descriptive statistics and chi-squared tests were 
used to calculate for differences in proportions. We considered a Gleason score 
≥ 3+4 being csPCa.
Results and limitations  PCa was diagnosed in 35% (55/156), 60% (223/373) and 
91% (479/528) in patients with PI-RADS 3, 4 and 5 respectively and csPCa in 17% 
(26/156), 34% (128/373) and 67% (352/528) respectively. Follow up of patients 
with negative biopsy findings resulted in csPCa in 1.7% (5/300) after a median 
period of 41 (IQR 25-50) months. The evaluation of prostate specific antigen 
density (PSAD) to predict csPCa resulted in 42% of patients with a PI-RADS3 that 
could avoid biopsy  in case a PSAD of  ≥ 0.15 ng/mL/mL would be used. In 6% (95% 
CI, 2-15) a csPCa would then be missed. The study is limited because of its 
retrospective character. 
Conclusion  MRGB in lesions scored PI-RADS ≥ 3 yields high detection rates of csPCa. 
in daily clinical practice in previous negative biopsy cases.
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prostatic extension (EPE). If none of the lesions demonstrate EPE, the largest 
tumor is considered the index lesion.5, 6 Analyses were performed with SPSS 
software (version 22, IBM). 
Follow up
Follow up until October 17, 2016 of patients with a negative MRGB result was obtained 
by reviewing our nationwide network and registry of histo- and cytopathology 
(PALGA). Prostate histology obtained by targeted or TRUS biopsy, transurethral 
resection of the prostate (TURP) or open prostatectomy were evaluated.
Results
After exclusion, 1057 patients left for analysis. Overall, 184 patients were biopsy 
naïve, 649 had a history of prior negative TRUS biopsy and 224 were on active 
surveillance with a GS 3+3. PI-RADS 3, 4 or 5 lesions were found in 156, 373 and 
528 patients respectively. A total of 1393 lesions were biopsied. Full patient char-
acteristics are presented in table 1. 
Biopsy results
PCa was detected in 72% (757/1057) of all patients. Biopsy in patients with PI-RADS 
3, 4 and 5 lesions resulted in PCa in 35% (55/156), 60% (223/373) and 91% (479/528) 
and resulted in csPCa in 17% (26/156), 34% (128/373) and 67% (352/528) 
respectively. In 67% (506/757) of all detected PCa and in 48% (506/1057) of all 
included patients, csPCa was detected. The csPCa detection rate was 50% (92/184) 
for patients without previous TRUS biopsy, 49% (319/649) for patients with prior 
negative TRUS biopsy and 42% (95/224) for patients in AS. In table 2, detailed PCa 
findings are listed.
 In table 3 biopsy pathology other than PCa is specified. Biopsy did not result 
in any pathology in 37.2%, 19.8% and 4.4% in PI-RADS 3, 4 and 5. Most commonly 
prostatitis is diagnosed next to PCa (9%). 
Follow up
After a median period of 41 (IQR 25-50) months, 82 of 300 patients without PCa at 
MRGB had follow up histology of the prostate. Targeted biopsy was performed in 49, 
TRUS biopsy in 14, TURP in 13 and open prostatectomy in 6 patients. Overall, in 1.7% 
(5/300) of all patients without PCa detected at biopsy, csPCa was found during 
follow up. In table 4, findings during follow up are specified.
Patients
All patients having MRGB and prior mpMRI in our institution between January 
2012 and September 2016 were identified. Patients with prior targeted biopsy, 
prior treatment of the prostate or with biopsy proven PCa ≥ 3+4 Gleason score (GS) 
were excluded from our study (fig. 1). Patients included in this study did not 
participate in other trials of our institution.         
Multiparametric MRI
Multiparemetric MRI was performed on a 3.0 T MR-scanner (Siemens, Skyra) with a 
pelvic phased-array coil. Owing to the large time span in which patients were 
included, there is a slight variation in mpMRI technical specifications, although it 
always met the PI-RADS criteria.
 Multiparametric MRI images were interpreted by six radiologists with a varying 
range of experience in prostate MR reading (2-20 years). All images were scored 
according to PI-RADs v1 or v2. In all patients, next to the PI-RADS score, PSAD is 
also measured. PSAD is calculated by dividing PSA blood level by the volume of 
the prostate; hereby, high PSA blood levels, for example, are corrected for large 
prostate volumes.
MRI-guided biopsy
During MRGB, performed in a separate session, patients were placed in the prone 
position with an MR compatible needle guide rectally inserted, attached to a biopsy 
device (Dynatrim, Invivo). Additional axial T2W and axial diffusion-weighted image 
were obtained to reproduce the location of the lesion. The needle guide was manually 
positioned using true fast imaging with steady-state free precession (TRUFI) images. 
Biopsy cores were obtained with an MR-compatible 18-gauge automatic biopsy gun. 
The position of the biopsy needle was confirmed with TRUFI images which were 
evaluated by one of the prostate MR experienced radiologists. We only performed 
targeted biopsy without additional random biopsy. Obtained pathological tissue 
was interpreted by dedicated uropathologists.
Data analysis
Patients were divided into cohorts based on their biopsy history (biopsy naïve, 
prior negative TRUS biopsy or in active surveillance (AS)). Descriptive statistics 
were used to present patient characteristics and detection rates within these 
different cohorts. We considered a Gleason score ≥ 3+4 being csPCa. Chi-square 
tests were used to calculate for differences in proportions. In patients with 
multiple lesions, an index lesion was determined according to PI-RADS. The index 
lesion is the one with the highest PI-RADS score. If an equal PI-RADS score is 
assigned to two or more lesions, the index lesion is the one that shows extra 
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Table 2  Prostate cancer detection
All patients
(n = 1057)
Biopsy naïve
(n = 184) 
Prior  
negative TRUS
(n = 649)
Active  
Surveillance
(n = 224)
PI-RADS 3, % (n) 14.8 (156) 9.2 (17) 16.3 (106) 14.7 (33)
No PCa 64.7 (101) 47.1 (8) 73.6 (78) 45.5 (15)
≤ 3+3 18.6 (29) 35.3 (6) 7.5 (8) 45.5 (15)
2+4 - - - -
3+4 9.0 (14) - 10.4 (11) 9.1 (3)
2+5 - - - -
4+3 5.1 (8) 11.8 (2) 5.7 (6) -
4+4 1.3 (2) 5.9 (1) 0.9 (1) -
3+5 0.6 (1) - 0.9 (1) -
5+3 - - - -
4+5 0.6 (1) - 0.9 (1) -
5+4 - - - -
5+5 - - - -
PI-RADS 4, % (n) 35.3 (373) 36.4 (67) 35.1 (228) 34.8 (78)
No PCa 40.2 (150) 38.8 (26) 44.3 (101) 29.5 (23)
≤ 3+3 25.2 (94) 29.9 (20) 20.6 (47) 34.6 (27)
2+4 0.3 (1) 1.5 (1) - -
3+4 22.2 (83) 20.9 (14) 21.5 (49) 25.6 (20)
2+5 - - - -
4+3 5.9 (22) 6.0 (4) 5.7 (13) 6.4 (5)
4+4 2.7 (10) 1.5 (1) 3.9 (9) -
3+5 1.3 (5) 1.5 (1) 1.3 (3) 1.3 (1)
5+3 - - - -
4+5 1.3 (5) - 1.3 (3) 2.6 (2)
5+4 0.8 (3) - 1.3 (3) -
5+5 - - - -
PI-RADS 5, % (n) 50.0 (528) 54.3 (100) 48.5 (315) 50.4 (113)
No PCa 9.3 (49) 9.0 (9) 9.8 (31) 8.0 (9)
≤ 3+3 23.9 (126) 22.0 (22) 20.3 (64) 35.4 (40)
2+4 0.2 (1) - 0.3 (1) -
3+4 29.7 (157) 28.0 (28) 30.8 (97) 28.3 (32)
2+5 0.2 (1) - 0.3 (1) -
4+3 15.7 (83) 22.0 (22) 15.9 (50) 9.7 (11)
4+4 10.0 (53) 8.0 (8) 11.1 (35) 8.8 (10)
3+5 2.8 (15) 2.0 (2) 2.2 (7) 5.3 (6)
5+3 0.8 (4) - 1.3 (4) -
4+5 5.9 (31) 5.0 (5) 7.0 (22) 3.5 (4)
5+4 1.3 (7) 4.0 (4) 0.6 (2) 0.9 (1)
5+5 0.2 (1) - 0.3 (1) -
TRUS = transrectal ultrasound guided biopsy; PI-RADS = Prostate Imaging Reporting And Data System; 
PCa = prostate cancer
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PSAD to predict csPCa
For each PI-RADS classification (PI-RADS 3,4 and 5) we examined the ability of 
different PSAD cutoff levels ranging from 0.1 to 0.25 to predict csPCa after initial 
biopsy (Supplementary table 1).
 Biopsying only patients with a PI-RADS 3 and a PSAD ≥ 0.15 ng/ml/ml results 
in 42% of patients with a PI-RADS 3 who would avoid biopsy. In 6% (95% CI, 2-15) 
of the patients who avoid biopsy, csPCa would be missed. Lowering the cutoff value 
to 0.12 ng/ml/ml results in 26% of patients with a PI-RADS 3 avoiding biopsy and 
in none of them (95% CI, 0-9) csPCa would have been missed (table 5). Applying 
the same cutoff values in patient with PI-RADS 4 would avoid MRGB in 38% and 
25% respectively. In 23% (95% CI, 17-31) and 20% (95% CI, 13-30) csPCa would have 
been missed, respectively.
 Within the cohort of patients with a PI-RADS 5 the percentages of missed 
csPCa would increase to 52% (95% CI, 43-60) and 45% (95% CI, 33-57) respectively, 
with these cutoff values.
Table 3  Pathology findings in 300 patients without detected prostate cancer
PI-RADS 3,  
% (n)
PI-RADS 4,  
% (n)
PI-RADS 5,  
% (n)
Prostatitis 15.4 (24) 14.5 (54) 3.2 (17)
High grade PIN 5.8 (9) 1.9 (7) 0.4 (2)
Granulomatous inflammation 1.3 (2) 1.1 (4) 0.6 (3) 
Atrophia 3.8 (6) 2.4 (9) 0.6 (3)
Atypical adenomatous hyperplasia 1.3 (2) 0.5 (2) 0.2 (1)
No pathology 37.2 (58) 19.8 (74) 4.4 (23)
PI-RADS = Prostate Imaging Reporting And Data System; PIN = prostatic intraepithelial neoplasia.
Table 4  Follow up of 300 patients without detected prostate cancer
No PCa GS 3+3 GS ≥ 3+4 No follow up
PI-RADS 3, % (n) 17.8 (18) 5.9 (6) 1.0 (1) 75.2 (76)
PI-RADS 4 22.7 (34) 3.3 (5) 2.0 (3) 72.0 (108)
PI-RADS 5 20.4 (10) 8.2 (4)  2.0 (1) 69.4 (34)
Total 20.7 (62) 5.0 (15) 1.7 (5) 72.7 (218)
PCa = prostate cancer; GS = Gleason score; PI-RADS =  Prostate Imaging Reporting And Data System
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Prostate cancer detection differentiated per location
Of all index lesions, 32% (n = 343) was located within the transition zone (TZ), 46% 
(n = 489) within the peripheral zone (PZ) and 21% (n = 225) of the lesions were 
overlapping both zones. The csPCa detection rates between the different zones 
differ significantly from each other (p <0.01) with a detection rate of 52% (n = 177), 
41% (n = 198) and 58% (n = 131) respectively. Within the three cohorts, this difference 
is seen only in patients with prior negative TRUS biopsy (p < 0.01) but not in biopsy 
naïve patients (p = 0.85) or in patients in AS (p = 0.44) (table 6). The csPCa 
detection rate within the PZ in men with prior negative TRUS biopsy (35%) is 
significantly lower compared to the detection rates in the same location in the 
cohort of biopsy naïve patients (51%, p < 0.01) but not in the cohort of patients in 
AS (42%, p = 0.17). In figure 2 and table 7, locations of the lesions are stratified 
into the following regions: base, midportion and the apex of the prostate.
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Table 6   Location of csPCa detection displayed per PI-RADS classification  
and per cohort
Transition zone 
(TZ)
Peripheral zone 
(PZ)
Overlap TZ  
and PZ
P value
PI-RADS, % (n) 
3 23 (14/61) 11 (8/72) 17 (4/23) 0.19
4  45 (59/131) 27 (51/189) 34 (18/53) <0.01
5  69 (104/151)  61 (139/228) 73 (109/149) 0.04
Cohorts, % (n) 
Biopsy naïve 50 (18/36) 51 (56/109) 46 (18/39) 0.85
Prior negative TRUS 55 (139/254) 35 (85/244) 63 (95/151) <0.01
Active Surveillance 38 (20/53) 42 (57/136) 51 (18/35) 0.44
Total 52 (177/343) 41 (198/489) 58 (131/225) <0.01
Chi-squared tests were used to calculate for differences in proportions between the zones.
csPCa = clinically significant prostate cancer; PI-RADS = Prostate Imaging Reporting And Data System; 
TRUS = transrectal ultrasound guided biopsy
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Biopsy of lesions next to the index lesion
In 298 (28%) patients, one (n = 260) or two (n = 38) other lesions were biopsied 
next to the index lesion. Overall, in 10% (n = 29) of patients with a second or a 
third suspicious lesion, the other lesion harbored a more aggressive PCa than the 
index lesion did. In 3% (n = 9) the index lesion did not result in the detection of 
PCa at all, whereas the other lesion did harbor GS 3+3 (n = 6), GS 3+4 (n = 2) or GS 
4+3 (n = 1). In 4% (n = 11) a GS 3+3 detected in the index lesion was overshadowed 
by the detection of a GS 3+4 (n = 9) or a GS 4+3 (n = 2) in another lesion and in an 
additional 3% (n = 9) a GS 3+4 or a GS 4+3 was found in the index lesion while a 
more aggressive tumor was found in the second or third lesion.         
Discussion
Our study demonstrates the largest cohort of MRGB in patients with suspicious 
lesions scored according to PI-RADS representing daily clinical practice.
 As expected, (cs)PCa detection increases with a higher PI-RADS level. The majority 
of detected PCa is clinically significant. These results are largely similar to results 
presented by other groups, although, a direct comparison is hard to perform as 
other groups, for example, included a low number of patients, did not differentiate 
between the PI-RADS scores or used a 1.5 Tesla MRI instead of a 3.0 Tesla.7-12 
Results between the three cohorts are quite similar, although, in patients in AS 
the detection of insignificant PCa is higher and the detection of csPCa is lower 
compared to the other cohorts. In patients in AS, GS 3+3 PCa is already proven to 
be present, this increases the yield of insignificant PCa within this cohort.
Figure 1  Patient flow chart
MRGB = Direct in-bore magnetic resonance imaging guided prostate biopsy; PI-RADS = Prostate Imaging 
Reporting And Data System; PCa = prostate cancer; GS = Gleason score.
Patients with MRGB 
of PI-RADS ≥ 3
(n = 1393)
Excluded (n = 336) 
- Prior targeted biopsy (n = 125)
- Prior treatment of PCa (n = 206)
- Prior GS ≥ 3+4 (n = 5)
Included patients
(n = 1057)
PI-RADS 4
(n = 373)
PI-RADS 3
(n = 156)
PI-RADS 5
(n = 528)
Figure 2  Detection rates differentiated per location
Clinically significant prostate cancer (csPCa) detection rates (%, n) are displayed based on the location 
of the lesion detected on multiparametric magnetic resonance imaging. E.g. The csPCa detection rate for 
lesions covering both the mid and apex region of the prostate is 57% (83/145). In table 7, the csPCa 
detection rates per subcohort are displayed.
Table 7  Location and csPCa detection rates stratified per cohort
(n = 1057) Biopsy naïve
(n = 184)
% (n)
Prior negative TRUS
(n = 649)
% (n) 
Active Surveillance
(n= 224)
% (n)
Apex 39 (16/41) 52 (85/163) 34 (20/59)
Apex/Mid 76 (16/21) 57 (50/88) 47 (17/36)
Mid 47 (32/68) 39 (66/168) 37 (27/73)
Mid/Base 48 (12/25) 66 (57/87) 65 (13/20)
Base 38 (6/16) 28 (27/95) 33 (8/24)
Apex-Base 77 (10/13) 71 (34/48) 83 (10/12)
In figure 2 the entire cohort is displayed. For example, the detection rate of csPCa of lesions covering 
the entire prostate (Apex-Base) in biopsy naïve patients is 77% (10/13).
csPCa = clinically significant prostate cancer; TRUS = transrectal ultrasound guided biopsy
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compared with the TZ. Most remarkable in the csPCa detection rates stratified in 
apex, midgland and base are the higher detection rates in lesions overlapping 
those regions. This may well be explained by the fact that such lesions are probably 
larger and thus more likely to be csPCa. Especially in lesions that reach from apex 
to base, high csPCa detection rates are reached. 
 Further, our data provide information about the detection of PCa in lesions 
which are not classified as the index lesion. We detected that in 10% of patients 
who have had a biopsy in two or more lesions, the index lesion harbored less 
aggressive PCa compared with the second or third lesion. These findings support 
the importance of biopsying multiple lesions in case different lesions are detected 
at mpMRI, as encouraged by PI-RADS version 2.6 
 As far as we know, PI-RADS and MRGB were never evaluated with such a number 
of patients as we now presented, which allowed us to address several aspects of 
PI-RADS and subsequent targeted biopsy. This study, however, has some limitations 
as well. The most important limitation is the retrospective nature of the study. 
Retrospective studies are known for their risk of selection bias. In addition, a 
consequence of the retrospective design is the assessment of mpMRI images by 
different radiologists. Some radiologists involved were highly experienced whereas 
others were less experienced. Moreover, each radiologist has his/her own way for 
measuring, for example, prostate size. On the contrary, an advantage of this is 
that it represents the daily practice we have to deal with. However, we are aware 
of the fact that our institution is experienced in both prostate mpMRI reading and 
MRGB. As a consequence, results may be difficult to extrapolate to hospitals with 
less experience. This study is further limited by the inclusion of patients with 
differing biopsy histories. To compensate for this limitation, we displayed the 
biopsy results for each cohort separately as well as all results together. The 
advantage is that we were able to demonstrate the effect a biopsy history has on 
PCa detection. Unfortunately, the presented follow up in this study is hampered 
for two reasons. First, due to the retrospective design, no uniform protocol for 
follow up was used. Therefore, follow-up consists of targeted, TRUS, TURP and open 
prostatectomy data. Second, the follow-up data were obtained by reviewing a 
nationwide network and registry of pathology. As a consequence, we do not know 
about follow-up of patients without pathology. Prospective studies evaluating long 
term follow-up after negative biopsies in patients with suspicious lesions are 
needed to determine the consequences of such a negative biopsy and to comment 
on the follow-up strategies in such patients. In our study, over 70% did not have 
follow-up histology. Unfortunately we do not know about any PSA or mpMRI in 
these patients. The final limitation of this study might be the use of both PI-RADS 
v1 and PI-RADS v2. Although, the consequence of this is probably limited as 
Further, we demonstrated that follow up in patients with negative MRGB findings 
despite a suspicious finding on prior mpMRI rarely results in csPCa (1.7%). Although 
patients with a lesion scored PI-RADS 5 are highly likely to have csPCa, in 33% we 
did not detect csPCa and in 9% we did not detect any PCa. In part, this may be 
explained by pathology which mimic PCa, for example prostatitis or fibrosis. By 
contrast, benign prostatic hyperplasia (BPH) also often disturbs the assessment of 
prostate mpMRI. A highly vascularised BPH nodule, for example, is sometimes 
incorrectly scored PI-RADS 5.
 An important finding of our study is the ability of PSAD to predict biopsy 
outcome in patients with PI-RADS 3 lesions. Recently, Washino et al.13 revealed 
that the PI-RADS score and PSAD were independent factors to predict csPCa and 
they stated that patients with a PI-RADS ≤ 3 and a PSAD of < 0.15 ng/ml/ml could 
avoid unnecessary biopsy. Owing to the known high NPV of PI-RADS in lesions 
classified ≤ 2 with values up to 98-100%, these lesions are not biopsied in our 
hospital, regardless of the PSAD. 8, 14, 15 Our findings now demonstrate that up to 
42% of patients with a PI-RADS 3 classification avoid biopsy when you would 
decide not to biopsy patients with a PI-RADS 3 and a PSAD below 0.15 ng/ml/ml . 
In 2-15% of them, csPCa would then be missed. Owing to a higher prevalence of 
csPCa in patients with a PI-RADS 4 or 5 lesion, PSAD is not useful as a tool to avoid 
unnecessary biopsy within these cohorts.
 More recently, Hansen et al.15 also evaluated the combination of PI-RADS and 
PSAD to avoid biopsy in patients with PI-RADS 3 lesions. Based on their and our 
findings we now suggest avoiding targeted biopsy in patients with a PI-RADS 3 
lesion and a PSAD below 0.15 ng/mL/mL. As PSAD incorporates prostate volume, 
our findings may even support the concept of using prostate volume and PSA blood 
level together in risk calculators, even before adding prostate imaging in the 
diagnostic workup. However, the evaluations that we performed specifically 
address the use of PSAD in patients with a PI-RADS 3, 4 or 5 lesion.    
Another interesting finding of our study is that in patients with prior negative 
TRUS biopsy, a suspicious lesion seen in the PZ is significantly less likely to be 
csPCa compared to other zones or compared to lesions in the PZ in biopsy naïve 
patients. Previously, Schouten et al.16 stated that in patients with prior negative 
TRUS biopsy, the majority of PCa was detected in the transition zone. Our results 
confirm these findings, and in addition, we detected that the assessment of the PZ 
is disturbed in patients with prior negative TRUS biopsy resulting in a lower 
detection rate. First, this can be explained by the fact that the PZ is already 
presampled in patients with prior TRUS biopsy, making the yield of additional 
biopsies in the same area poorer. Second, prostatitis and fibrosis caused by TRUS 
biopsy mimic and mask PCa in the PZ and thus cause a lower PCa detection 
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Conclusions
MRGB in previous negative biopsy cases yields high csPCa detection rates in 
PI-RADS ≥ 3 and the use of PSAD in patients with PI-RADS 3 enables them to avoid 
unnecessary biopsy. Despite the high performance of mpMRI and MRGB, in some 
patients with suspicious mpMRI findings pathology does not reveal PCa. However, 
follow-up histology in such patients rarely results in csPCa. Additional research 
with prospectively collected data is needed to verify our findings.
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Introduction
Several major changes have taken place in the last decade regarding the diagnosis 
of prostate cancer (PCa). Most important is the introduction of multiparametric 
magnetic resonance imaging (mpMRI). mpMRI allowed for an accurate detection 
and localization of clinically significant (cs)PCa. It also made it possible to perform 
targeted biopsy instead of 10-12 core systematic transrectal ultrasound (TRUS) 
guided biopsy and it thus enables to reduce the number of biopsy needles.1,2 
Nowadays, mpMRI is recommended by the European Association of Urology (EAU) 
in men with a persistent clinical suspicion of PCa despite a negative TRUS biopsy.3 
These recommendations are made because TRUS biopsy is under-diagnosing csPCa, 
especially in lesions anteriorly located in the prostate.4
 After mpMRI, suspicious areas can be targeted using the obtained information. 
Targeted biopsy can be done, for example, direct in-bore MR-guided (MRGB). MRGB 
is able to accurately target suspicious lesions; however, the procedure is time-
consuming, expensive and in most countries very limited accessible.5,6 For these 
reasons, MRI-TRUS fusion guided biopsy (FGB) is more commonly performed. In 
FGB, previously obtained mpMRI information is fused (cognitively or software 
assisted) with real-time TRUS images. MR “slot-time” can be saved because the 
biopsy can be performed ultrasound-guided rather than MR-guided. This enable 
the procedure to be less expensive and much more readily available. Also, FGB 
allows a urologist to perform a 10-12 core systematic TRUS biopsy in addition to 
targeted biopsy as systematic TRUS biopsy still detects csPCa in up to 10% of 
patients which would be missed in a targeted only-approach.7-9 In our institution, 
only patients with lesions larger than 8mm measured in at least one direction are 
considered eligible for FGB as we expected FGB in those lesions to be as accurate as 
MRGB.10,11
 With FGB and MRGB increasingly being practiced, there is a need to determine 
whether those techniques yields comparable csPCa detection rates. Nowadays, as 
far as we know, only one study was performed which compared the two targeted 
biopsy approaches.12 Therefore, the aim of our study is to compare the difference 
in the detection of csPCa between both biopsy procedures.
Abstract
Purpose  To compare clinically significant prostate cancer (csPCa) detection rates 
between Magnetic Resonance Imaging (MRI) – transrectal ultrasound (TRUS) 
fusion-guided prostate biopsy (FGB) and direct in-bore MRI-guided biopsy (MRGB).
Methods  We performed a comparison of csPCa detection rates between FGB and MRGB. 
Included patients had (1) at least one prior negative TRUS biopsy; (2) a Prostate 
Imaging Reporting and Data System (PI-RADS)  4 or 5 lesion and (3) a lesion size 
of ≥ 8mm measured in at least one direction. We considered a Gleason score ≥ 7 
being csPCa. Descriptive statistics with 95% confidence intervals (CI) were used to 
determine any differences.
Results  We included 51 patients with FGB (59% PI-RADS 4 and 41% PI-RADS 5) and 
227 patients with MRGB (34% PI-RADS 4 and 66% PI-RADS 5). Included patients 
had a median age of 69 years (IQR, 65-72) and a median PSA level of 11.0 ng/ml 
(IQR, 7.4-15.1) and a median age of 67 years (IQR, 61-70), the median PSA 12.8 ng/
ml (IQR, 9.1-19.0) within the FGB and the MRGB group respectively.  Detection rates 
of csPCA did not differ significantly between FGB and MRGB, 49% vs. 61% 
respectively
Conclusion  We did not detect significant differences between FGB and MRGB in 
the detection of csPCa. The differences in detection ratios between both biopsy 
techniques are narrow with an increasing lesion size. This study warrants further 
studies to optimize selection of best biopsy modality.
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Patients who preferred MRGB over FGB were offered MRGB and vice versa. FGB was 
performed by one radiologist without prior prostate biopsy experience.    
Direct in-bore MR-guided biopsy
During MRGB, patients are positioned in a prone position. A needle guide is rectally 
inserted. Prior to biopsy, additional axial T2W and axial DW images were made to 
confirm the localization of the lesion. True fast imaging with steady-state free 
precession (TRUFI) images were used to direct the manually adjustable needle 
guide. After each biopsy, the position of the needle was confirmed with TRUFI 
images. The accuracy of the needle position was assessed by one of the prostate MR 
experienced radiologists. No anesthetics were used during this procedure. All biopsies 
were performed transrectal without adding 10-12 core systematic TRUS biopsies. 
Procedure time is typically 45-60 minutes.
Histopathology
All biopsy cores were evaluated by one of three dedicated uropathologist. 
Pathologists were not blinded for the biopsy method or the mpMRI findings. We 
considered a Gleason score ≥ 7 being clinically significant. In case a patient does 
have multiple lesions, we used the index lesion (according to PI-RADS) for the 
analysis. In case a patient had a lesion next to the index lesion which did not 
match the inclusion criteria, we did biopsy the lesion, however, we did not evaluate 
the results in this study.
Statistical analysis
We used descriptive statistics with 95% confidence intervals (CI) with a continuity 
correction factor to calculate potential differences between the two techniques. 
Additionally, we used chi-square statistics to calculate for significant differences 
between cohorts. A p-value ≤ 0.05 was considered statistically significant. Analyses 
were conducted using IBM SPSS Statistics (Version 22).
Methods
Patients
In our institution, 82 patients had FGB between December 2014 and December 
2016. Of these patients, 51 met the next inclusion criteria: (1) at least one prior 
negative TRUS biopsy; (2) a Prostate Imaging Reporting and Data System (PI-RADS) 
4 or 5 lesion localized on prior mpMRI performed in our institution and (3) a lesion 
size of ≥ 8mm measured in at least one direction. To compare, we searched our 
institutional MRGB database, starting from January 2012. This reference database 
contained 227 patients with the same inclusion criteria.  The study was approved 
by our institutional review board.
mpMRI
mpMRI was performed on a 3.0 T MR-scanner (Siemens, Skyra) with a pelvic 
phased-array coil. Tri-planar anatomical T2- weighted images (T2W), axial dynamic 
contrast-enhanced images (DCE) and axial diffusion-weighted (DW) images were 
obtained. Images were analyzed and reported according to PI-RADS version 1 or 2 
by six radiologist with varying experience in prostate MR reading (2-20 yr).13,14
Software assisted registration
Prior to the FGB procedure, Digital Imaging and Communications in Medicine 
(DICOM) images were uploaded to the ultrasound device (Aplio 500, Toshiba Medical 
Systems). An electromagnetically (EM) tracking field generator was placed near 
the pelvis of the patient and an EM tracking sensor was attached to the free-hand 
operated transrectal ultrasound probe (PVT-781 VT) so that real-time movement 
tracking is allowed. Uploaded axial T2W images and ultrasound images were 
displayed side by side. Rigid image registration was acquired by selecting 
landmarks visible on both the ultrasound images and the uploaded T2W images. 
A landmark (e.g. cysts, verumontanum or BPH nodules) as close as possible to the 
suspicious lesion was chosen to enable the most reliable registration. After software 
assisted registration, we cognitively enhanced the fusion as rigid image registration 
is often distorted by the deformation of the prostate caused by the introduction of 
the ultrasound probe for example. We only performed targeted biopsy without 
additional 10-12 core random biopsy. Procedure time was typically 10-20 minutes. 
The procedure was performed without using anesthetics. The described registration 
method does not allow for a confirmation of the needle position in the prostate.
 As our institution was much more experienced in MRGB at the time of the 
introduction of FGB in our hospital, we offered FGB only to patients with a PI-RADS 
4 or 5 lesion and a lesion size of ≥ 8mm measured in at least one direction. Patients 
with smaller lesions and lesions scored PI-RADS 3 were immediately offered MRGB. 
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Prostate cancer detection
In patients having FGB, csPCa was detected in 49.0% (25/51) and any PCa in 66.7% 
(34/51). The csPCa detection rate in patients with PI-RADS 4 or 5 was 33.3% (10/30) 
and 71.4% (15/21) respectively. In these subcohorts, any PCa was detected in 56.7% 
(17/30) and 81.0% (17/21) respectively.
 The detection rates in patients having MRGB were 61.2% (139/227) for csPCa 
and 85.0% (193/227) for any PCa. This is a difference in favor of MRGB of 12.2 
(p = 0.11) and 18.3 (p <0.05) percentage points respectively.
The csPCa detection rates favored MRGB in patients with a lesion scored PI-RADS 4 
with 16.0 (p = 0.13) percentage points. In patients with PI-RADS 5, FGB reached a 
csPCa detection rate which was 4.1 (p = 0.71) percentage points higher than that 
of MRGB (table 2).
 Figure 1 and 2 represent the csPCa and any PCa detection rates respectively per 
(sub)cohort of both techniques with 95% confidence intervals. 
csPCa detection correlated to lesion size
Applying a minimal lesion size of 16mm instead of 8mm increases the csPCa 
detection rate from 49% (95% CI, 35.0-63.2)  to 61.5% (95% CI, 40.7-79.1) for FGB 
and from 61.2% (95% CI, 54.5-67.5) to 63.9% (95% CI, 55.1-71.9) for MRGB. Further 
increasing the minimal lesion size to 24mm results in a csPCa detection ratio of 
63.6% (95% CI, 31.6-87.6) and 67.3% (95% CI, 53.2-79.0) for FGB and MRGB 
respectively. In figure 3 the detection ratios for csPCa are displayed correlated 
with the minimal lesion size. 
Results
Patient characteristics
The 51 included patients having FGB had 58 lesions to target. Those patients had 
a median age of 69 years (IQR, 65-72) and a median PSA level of 11.0 ng/ml (IQR, 
7.4-15.1). They had a median of 2 (IQR, 1-2) previous negative TRUS biopsy sessions 
and had a median PSA density 0.18 ng/ml/ml (IQR, 0.1-0.3). Overall, 58.8% (30/51) 
were biopsied because of a PI-RADS 4 index lesion and 41.2% (21/50) because of 
PI-RADS 5.
 The 227 patients in the reference database having MRGB had 261 biopsied 
lesions. The median age was 67 years (IQR, 61-70), the median PSA 12.8 ng/ml 
(IQR, 9.1-19.0) and the median PSA density ng/ml/ml 0.23 (IQR, 0.15-0.40 ). 
Patients had a median of 2 (IQR, 1-3) prior negative TRUS biopsy sessions. Overall, 
33.9% (77/227) were biopsied because of a PI-RADS 4 index lesion and 66.1% 
(150/227) because of PI-RADS 5. Further patient and lesion characteristics are 
specified in table 1.
Table 1   Patient and lesion characteristics
Patient characteristics FGB (n = 51) MRGB (n = 227)
Age, yr, median (IQR) 69 (65-72) 67 (61-70)
PSA level, ng/ml, median (IQR) 11.0 (7.4-15.1) 12.8 (9.1-19)
Prostate volume, ml, median (IQR) 63.0 (46-86.0) 53.0 (36.5-78.0)
PSA density, ng/ml/ml, medain (IQR) 0.18 (0.1-0.3) 0.23 (0.15-0.4)
PI-RADS score index lesion, n (%) 
4 30 (58.8) 77 (33.9)
5 21 (41.2) 150 (66.1)
Time between mpMRI and biopsy, days, median (IQR) 28 (21-43) 29 (17-42)
No. of prior TRUS biopsies, median (IQR) 2 (1-2) 2 (1-3)
Lesion characteristics FGB (n =58 ) MRGB (n = 261)
PI-RADS score, n (%) 
4 37 (63.8) 101 (38.7)
5 21 (36.2) 160 (61.3)
Biopsies per lesion, n, median (IQR) 3 (2-3) 2 (2-3)
FGB = fusion guided biopsy; MRGB = direct in-bore magnetic resonance guided biopsy; yr = year; IQR = Inter 
quartile range; PSA = prostate specific antigen; PI-RADS = Prostate Imaging Reporting and Data System; 
mpMRI = multiparametric magnetic resonance imaging; TRUS = transrectal ultrasound guided biopsy
Table 2  Detection rates of (cs)PCa
Detection rates FGB (n = 51) MRGB (n = 227) Difference, (95% CI)
Overall
any PCa, % (n) 66.7 (34) 85.0 (193) 18.4 (5.0 – 33.7)
csPCa, % (n) 49.0 (25) 61.2 (139) 12.2 (-3.5 –  27.6)
PI-RADS 4 n = 30 n = 77
any PCa, % (n) 56.7 (17) 72.7 (56) 16.1 (-4.8 – 37.2)
csPCa, % (n) 33.3 (10) 49.4 (38) 16.0 (-6.6 – 35.3)
PI-RADS 5 n = 21 n = 150
any PCa, % (n) 81.0 (17) 91.3 (137) 10.4 (-3.7 – 34.2)
csPCa, % (n) 71.4 (15) 67.3 (101) 4.1 (-20.7 – 22.4)
FGB = fusion guided biopsy; MRGB = direct in-bore magnetic resonance guided biopsy; PCa = prostate 
cancer; cs = clinically significant (Gleason score ≥ 7); PI-RADS = Prostate Imaging Reporting and Data 
System. Differences are shown in percentage points
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The detection rate of any PCa for FGB increases from 66.7% (95% CI, 52.0-78.9) with 
a minimal lesion size of 8mm to 73.1% (95% CI, 52.0-87.7) and 81.8% (95% CI, 
47.8-96.8) in case lesions of 16mm or 24mm would have been biopsied respectively. 
Detection rates of any PCa for MRGB would increase from 85.0% (95% CI, 79.6-89.3) 
to 88.7%(95% CI, 81.8-93.3) and 90.9% (95% CI, 79.3-96.6) applying a minimal 
biopsy threshold of 16 and 24mm respectively. In figure 4 we supplied the detection 
rates of any PCa with 95% CI with different minimal lesion sizes.
Follow up after negative fusion guided biopsy
Within the cohort of 17 patients with a negative biopsy outcome after FGB, two 
patients a follow up (FU) MRGB performed within two months. In both PCa was 
detected: in one a GS 3+3 and in one a GS 2+3. In one patient, a radiologist 
downgraded the level of suspicion from PI-RADS 5 to PI-RADS 2 after another 
mpMRI was performed a year after FGB. In another five patients, PSA decreased 
and therefore no follow up mpMRI was performed. In the remaining nine patients, 
follow up is unknown.
Figure 1  CsPCa detection of FGB and MRGB
CsPCa detection rates of FGB and MRGB displayed overall and per PI-RADS classification. The bar chart 
represents the detection rates and the black lines indicate the 95% confidence intervals.
csPCa = clinically significant prostate cancer (Gleason score ≥ 7); FGB = fusion guided biopsy; direct 
in-bore magnetic resonance imaging guided biopsy; PI-RADS = Prostate Imaging Reporting and Data 
System
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Figure 2  Any PCa detection of FGB and MRGB
PCa detection rates of FGB and MRGB displayed overall and per PI-RADS classification. The bar charts 
represent the detection rates and the black lines indicate the 95% confidence intervals.
PCa = prostate cancer; FGB = fusion guided biopsy; MRGB = direct in-bore magnetic resonance imaging 
guided biopsy; PI-RADS = Prostate Imaging Reporting and Data System
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Figure 3  csPCa detection with different lesion sizes
csPCa detection rates and 95% CI for both FGB and MRGB with different lesion sizes in millimeters. The 
dotted lines represent the 95% CI. csPCa = clinically significant prostate cancer; CI = confidence interval; 
FGB = fusion guided biposy; MRGB = direct in-bore magnetic resonance imaging guided biopsy; mm= 
millimeter
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Arsov et al., this could be well explained by the differences in used inclusion criteria. 
We only included patients with lesions scored PI-RADS 4 or 5 and a minimal lesion 
size of 8mm. Therefore our results cannot be reliably compared with their results.
 Comparing the cohorts in our study for PI-RADS 4 and 5 separately, we 
demonstrated a slightly lower csPCa detection rate in PI-RADS 4 lesions for FGB, 
although, this result was not statistically significant. On the other hand, in 
patients with a PI-RADS 5 lesion, the detection rate of csPCa is slightly higher in 
the cohort having FGB, again, this was not a statistically significant difference. 
The higher detection rate for FGB in lesions score PI-RADS 5 is probably caused by 
the fact that a PI-RADS 5 lesion is most commonly larger than a lesion scored 
PI-RADS 4. With both FGB and MRGB experience, we noticed that larger lesions and 
lesions with a PI-RADS score of 5 are often visible on ultrasound during FGB, which 
allowed us to target such lesions accurately. This is supported by the results of our 
evaluation of detection rates correlated to the lesion size as displayed in figure 3 
and 4. The difference in detection rates between the two biopsy techniques 
narrows when applying a higher threshold for the minimal lesion size. These 
results however should be evaluated with caution. The sample size is getting 
smaller when increasing the threshold of the lesion size and, as a consequence, the 
95% CI is widening. However, in our institution, both FGB and MRGB are being 
practiced. As we used a fusion platform based on rigid image registration, a cognitive 
enhancement is required to biopsy a suspicious lesion reliably. This enhancement 
is most reliable in case a lesion appears to be visible on gray scale ultrasound after 
the software assisted rigid image registration is completed. We observed that most 
cases required a cognitive enhancement. Though, in most cases cognitive enhancement 
was possible as lesions often appears to be visible on grayscale ultrasound after 
the software assisted image registration was performed. Especially the lesions scored 
PI-RADS 5 and the lesions with a larger diameter. This suggestion is supported by 
the presented data as the detection rate of csPCa in lesions scored PI-RADS 5 are 
almost equal between both biopsy techniques. Further, the differences in detection 
rates of both biopsy techniques narrows when applying a higher threshold of 
lesions sizes from where to biopsy. A further increase in ultrasound visibility of 
lesions may be reached by adding other ultrasound modalities like power Doppler 
or elastography, this may increase the diagnostic accuracy of FGB based on a rigid 
image registration system.15,16
 At the moment, the studies investigating csPCa detection rates between 
different MR targeted biopsy approaches did not detect statistically significant 
differences. In our study this may be explained by the use of a retrospective study 
design with a relatively small sample size, which is an important limitation of our 
study. A prospective trial should be performed to investigate potential relevant 
differences between both biopsy techniques. Unfortunately, the prospective trial 
Discussion
This study evaluated the performance of FGB compared to MRGB. We did not detect 
statistically significant differences between FGB and MRGB for csPCa in patients 
with lesions scored PI-RADS 4 or 5 with a minimal lesion size of 8mm measured in 
at least one direction (49% vs 61%). We neither detected statistically significant 
differences when evaluating the results for PI-RADS 4 and 5 separately.   
 As far as we know, at the moment, only Arsov et al.12 performed a study in 
which two MR-targeted prostate biopsy approaches were compared. They compared 
PCa detection rates between an MRGB approach alone and a FGB approach combined 
with systematic TRUS biopsy. As interim analyses did not identify an important 
improvement in detection rates for the combined approach, the study was halted. 
Evaluating their results, exclusively comparing the two targeted biopsy approaches, 
in-bore biopsy reaches a csPCa detection rate of 29% (31/106) compared to a 
detection rate of 26% (27/104) in patients having FGB.
 As Arsov et al, we did not detect significant differences in csPCa detection 
rates. Remarkably, the csPCa detection rates in our study are higher than those of 
Figure 4  Any PCa detection with different lesion sizes
Any PCa detection rates and 95% CI for both FGB and MRGB with different lesion sizes in millimeters. 
The dotted lines represent the 95% CI. PCa = prostate cancer; CI = confidence interval; FGB = fusion 
guided biposy; MRGB = direct in-bore magnetic resonance imaging guided biopsy; mm= millimeter
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Conclusion
We did not detect significant differences between FGB and MRGB in the detection 
of csPCa. The differences in detection ratios between both biopsy techniques 
narrows with an increasing lesion size. This study warrants further studies to 
optimize selection of best biopsy modality.
of Arsov et al.12, which tried to address this issue, was halted and thus did not 
reach their required sample size. Of course, the question arises which differences 
in detection rates are allowed as FGB is less expensive compared to MRGB and it 
thus may be less accurate. To assess the required diagnostic accuracy of FGB, 
Health Technology Assessment studies could be helpful.
 A limitation of our study is that we performed a single centre study. As a 
consequence, we performed FGB and MRGB on one type of machine, while nowadays, 
several commercially available platforms are used worldwide. In the future, 
a multicentre study could solve this limitation.
 In our institution, only patients with lesions larger than 8mm measured in at 
least one direction are considered eligible for FGB as we beforehand expected FGB 
to be slightly less accurate than MRGB. Thus, the results of this study does not 
cover lesions which are quite small. This raises the question whether FGB is an 
appropriate technique to target such small lesions. Unfortunately, our data is not 
appropriate to address this question.
 Another limitation of our study is the different number of included patients 
in both cohorts making comparisons difficult. It would have been desirable to 
increase the FGB cohort, for instance to eliminate the learning curve we had. To 
maximize the MRGB cohort, we used a longer inclusion for that cohort. It is clear 
that our institution is much more experienced in MRGB than in FGB which may 
introduce a bias in favor of MRGB. Unfortunately, FGB was introduced in our 
institution at a later time. 
 A last limitation of our study is the distribution of PI-RADS 4 and 5 in both 
subgroups. The FGB cohort consists of approximately 40% of patients with a 
PI-RADS 5 lesion while this almost 70% in the MRGB cohort. This is likely to 
influence the results in favor of MRGB.     
 Our findings support our persuasion of FGB having an important role in the 
diagnosis of csPCa in patients with suspicious lesions seen on mpMRI, especially in 
larger lesions. Compared to MRGB, FGB is a relatively simple technique to implement 
in urologist’s practice. Procedure time for example is considerably shorter for FGB. 
Further, in most countries MR “slot-time” is expensive and very limited available 
making FGB a less expensive and thus a more attractive procedure. Further, FGB 
allows you to perform 10-12 core systematic TRUS biopsy next to targeted biopsy 
which may be important as several studies are reporting up to 10% of detected 
csPCa with systematic biopsy which would be missed in a targeted-only approach.7,8 
MRGB appears to be a method reserved for the institutions that are in the position 
to use MR “slot-time” for this procedure.    
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Introduction
Since its introduction, multiparametric magnetic resonance imaging (mpMRI) of 
the prostate and subsequent targeted biopsy improved the detection of clinically 
significant prostate cancer (csPCa), without increasing the detection of insignificant 
prostate cancer when (PCa) compared to a systematic transrectal ultrasound 
(TRUS)-guided biopsy.1-3 Reported csPCa detection rates of the targeted biopsy 
(e.g., fusion-guided or direct in-bore MR targeted) in men with a suspicious lesion 
ranged from 17-52%, with several reasons for this serious range. Some of these 
reasons are the diverse definitions for csPCa, the various thresholds from where a 
lesion is biopsied, the ranging MRI protocols and the differences in study protocols 
being either prospective or retrospective.1, 4-9 Detection rates for any PCa even 
ranges from 22-79% in men with lesions detected on prebiopsy mpMRI.4, 6, 10, 11 
Contrariwise, when a biopsy did not reveal any PCa in 21-78% of those men, 
although they had a suspicious lesion seen on mpMRI. In our institution, such 
patients, in whom direct in-bore MR-targeted biopsy (MRGB) was negative despite 
a suspicious lesion, are frequently followed by measuring the serum prostate-spe-
cific antigen (PSA) and if required, obtaining another mpMRI or even repeating 
theMRGB. Consequently, additional costs are being made and patients are subjected 
to risks and  the inconvenience associated with it.
 Previously, Chelluri et al.12 described their findings in 90 men having a second 
MRI-TRUS fusion guided biopsy after the first one was negative, yielding a 6.0% 
Gleason score ≥ 3+4 lesions. In addition,  recently Costa et al.13 presented their 
results yielding 40% of intermediate and high risk cancers with repeat targeted 
biopsies or surgeries in 38 highly suspicious lesions with an initial negative 
MRI-TRUS fusion targeted prostate biopsy.
 To our knowledge, the yield of repeated MRGB in this particular clinical 
scenario is not well established. This is especially interesting as direct in-bore MR 
targeted biopsy is still the most accurate prostate biopsy technique. 7, 14, 15 
Therefore, the aim of our paper was to determine the yield of repeat direct in-bore 
MRGB (MRGB-2) in patients having a negative first one (MRGB-1) and to correlate 
with clinical parameters and to present subgroup analyses of patients with positive 
repeat biopsies despite having negative initial biopsies.
Abstract
Background  This  study’s endpoints were to determine the yield of repeat MRGB 
(MRGB-2) after the first one was found to be negative (MRGB-1), in order to 
correlate with clinical parameters and to present the subgroup analyses of patients 
with positive repeat biopsies, despite having  a negative initial biopsies.
Materials and Methods  We retrospectively included patients with MRGB-2 after a 
negative MRGB-1 both between January 2006 and August 2016. All anonymized 
MRI data were retrospectively reassessed according to the PI-RADS version 2 by 
two radiologists. Images of MRGB were compared to determine whether the same 
prostate lesion was biopsied during MRGB-1 and MRGB-2. Descriptive statistics 
were utilized  to determine the yield of clinically significant prostate cancer 
(csPCa) at MRGB-2. Gleason score of ≥3+4 was considered csPCa. This study included 
62 patients (median age, 63 years; interquartile range [IQR], 58-66 years) with 75 
sampled lesions during MRGB-2 left for analysis, and 63 lesions were resampled and 
12 new lesions were sampled. Included are patients who had a prostate-specific 
antigen (PSA) at MRGB-1 of 13 ng/ml (IQR,5.8-20) and a PSA at MRGB-2 of 15 ng/
ml (9.0-23).
Results  In 16/75 (21%) lesions csPCa was detected during MRGB-2. Of 63 resampled 
lesions, 13 (21%) harbored csPCa at MRGB-2. In two patients, csPCa was detected 
on  repeat biopsy, while the volume of the lesion decreased between MRGB-1 and 
MRGB-2.   
                        
Conclusion  We concluded that patients could benefit from repeat biopsy after 
negative initial MRGB, especially in the case of increasing PSA values and persisting 
PCa suspicion in MRI. Further research is needed to establish predictors for positive 
repeat targeted biopsies.
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Materials and Methods
This retrospective study was approved by our institutional review board with a 
waiver of informed consent (2016-2767).
Patients
The Picture Archiving and Communication System (PACS) data was searched for 
patients who had at least two consecutive MRGBs in our institution between 
January 2006 and August 2016. Patients were excluded if any PCa was detected 
before MRGB-1 or between MRGB-1 and MRGB-2. Thus, included patients did not 
have a  biopsy proven PCa before MRGB-1, had a negative MRGB-1, had a lesion 
which was rebiopsied during MRGB-2 and had an mpMRI before MRGB-1 (figure 1). 
As a consequence of these  criteria, we could not provide the results of the overall 
detection rates during MRGB-1 or MRGB-2.  
 In 81 patients, an MRGB was performed twice in the same patient between 
January 2006 and August 2016. Of those patients, 19 were excluded because they 
had a GS 3+3 after MRGB-1.
 After exclusion, 62 patients were included with 98 lesions biopsied during 
MRGB-1. Seven patients were biopsy negative prior to MRGB-1. During MRGB-2, 63 
of those lesions were rebiopsied and 12 new lesions were found. In 3 out of these 
12 new biopsied lesions, csPCa was detected. Overall, 35 lesions biopsied during 
MRGB-1 were not rebiopsied during MRGB-2 (Figure 1), because they were not 
visible anymore or not suspicious for csPCa at mpMRI-2 (i.e., PI-RADS classification 
1 or 2). However,  because of a lack of pathologic confirmation in those lesions, we 
did not evaluate this any further. Patient characteristics can be found in Table 1.
MpMRI and MRGB specifications
MRI was performed on a 3T MR-scanner (Siemens, Skyra), with a pelvic phased-array 
coil. In four patients an endorectal coil was utilized during first mpMRI instead of 
a pelvic phased-array coil. In all patients, tri-planar anatomical T2-weighted 
images (T2WI), axial dynamic contrast-enhanced images (DCE) and axial diffusion- 
weighted images (DWI) were usually obtained. However, because of the large time 
span in which patients were included, there is a slight variation in mpMRI technical 
specifications. A typical T2WI sequence had a repetition time (TR) of 3540 ms 
(range, 3000-7170), an echo time (TE) of 104 ms (range, 99-121), a flip angle of 
120 degrees (range, 120-170), a turbo factor of 15 (range, 15-25), a matrix of 
320  320 pixels (range, 224  448 - 384  384), and a slice thickness of 3 mm 
(range, 3-4), with 15 to 27 slices were needed to cover the entire prostate. 
DWI typically consisted of a calculated ADC map and multiple b-values (0, 50, 500, 
800, 1400), a matrix of 128 108 pixels (range, 100  100 – 144 x 192) with a slice 
Figure 1   Flowchart and in- and exclusion criteria of patients with repeat MRGB  
in our institution
MRGB = magnetic resonance imaging guided biopsy; GS = Gleason score; PCa = prostate cancer; mpMRI = 
multiparametric magnetic resonance imaging; cs = clinically significant
Twice MRGB
N = 81
Excluded
(GS 3+3 at MRGB-1)
N = 19 
Twice MRGB
without any PCa
at MRGB -1
N = 62 
Twice MRGB and
mpMRI without
any Pca at
MRGB -1
N = 47   
Excluded
(no mpMRI before MRGB-2)
N = 15 
Lesions
biopsied at
MRGB -1
N = 83  
N = 48 
csPCa
N = 9 
No csPCa
N = 39 
No csPCa
N = 9 
New lesions
biopsied at
MRGB -2
Lesions not
rebiopsied at
MRGB -2
Lesions
rebiopsied at
MRGB -2
N = 12 
csPCa
N = 4 
No csPCa
N = 11 
N = 35 
csPCa
N = 3 
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thickness of 4 mm (range, 3-5) with 20 (range, 15-23) slices to cover the prostate. 
DCE was obtained using 15 ml gadoterate meglumine (Dotarem; Guerbet LCC, 
Bloomington, IN, USA) with an injection rate of 2.5 ml/s followed by a 20 ml NaCl 
flush, an acquisition time of 2.5 min (range, 2-6) and a TR of 32 ms (range, 32-44). 
Patient characteristics are listed in table 1, and follow up after MRGB-2 until 
September 15, 2017 were acquired from hospital records by one observer (WV).
 During MRGB, patients were placed in the prone position with an MR-compatible 
needle guide rectally inserted. The needle guide was attached to a biopsy device 
DynaTRIM (Invivo corp., Gainesvill, FL, USA). During the MRGB session, axial T2WI 
and axial DWI were obtained to reproduce a lesion’s location. The needle guide was 
manually positioned using true fast imaging with steady-state free precession 
(TRUFI) images. An MR-compatible 18-gauge biopsy gun was used to obtain biopsy 
cores. The lengths of the obtained cores were 17 mm. Usually, two cores per lesion 
are obtained. Immediately after the biopsy, with the biopsy needle still inserted, 
TRUFI images in two directions were obtained to confirm biopsy position. 
The position of the needle was assessed by one of the radiologists experienced 
in prostate MR readings. In case there is uncertainty about the accuracy of a needle, 
a third biopsy core was obtained. The ideal location of the needle is when the tip 
is piercing through the lesion as the tip of the needle does not obtain tissue. 
During MRGB, no anesthetics were utilized. Obtained pathological tissue was 
interpreted by dedicated pathologists with 20-30 years of experience in prostate 
specimen analysis. Procedure time for MRGB was typically 45-60 min.   
MpMRI analysis
Nowadays, in our institution, the threshold for biopsying a lesion is PI-RADS ≥ 3. 
However, as patients had mpMRI and MRGB before 2012, not every lesion included 
was scored according to PI-RADS. Therefore, for this study, mpMRI images were 
anonymized and they were reassessed according to the Prostate Imaging - 
Reporting and Data System (PI-RADS) version 2 by two radiologists with 5 and 
17 years of experience in prostate MR readings (SJ and TT respectively).(16) 
Disagreements were  resolved by consulting a third reader with 12 years of experience 
in prostate MR readings (JF). MRGB images were used to assess whether the same 
lesion was rebiopsied during MRGB-2. Only the lesions which were biopsied twice 
were reassessed. In case other lesions were detected, we did not evaluate them in 
this study. Radiologists were blinded for pathological outcomes of MRGB-2 but 
were aware of the negative outcomes of MRGB-1. Lesion volume was calculated by the 
ellipsoid formula ([left-right  anterior-posterior  cranial-caudal diameter]  π/6). 
The averages of the calculated volumes were used in the analyses.   
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A moderate interobserver agreement between both radiologists for the PI-RADS 
classification for lesions at mpMRI was reached with a weighted kappa value of 0.57 
(95% confidence interval [CI], 0.36-0.78).  In none of the patients with a decreasing 
PSA between MRGB-1 and MRGB-2, csPCa was detected (Figure 6). In patients with 
repeat biopsies, MRGB-1 was mostly performed in years 2010 and 2011 (n = 34) with 
7 lesions resulting in csPCa at MRGB-2. MRGB-1 was never performed in year 2016 
(Figure 7).       
Follow up after negative MRGB-2
Three patients with  negative MRGB-2 had another MRGB (hereafter , MRGB-3). 
In none of them PCa was detected. Their reassessed PI-RADS scores were PI-RADS 
2, 4 and 5. In nine patients an mpMRI after MRGB-2 was obtained, those were 
assessed as being PI-RADS 2, no MRGB-3 was performed in those patients. In six 
patients no additional mpMRI was performed, because the PSA decreased after 
MRGB-2. In the remaining 45 patients, follow up data was not available.
Analysis
Descriptive statistics were used for the patient, lesion characteristics and the 
detection rates of MRGB-2. Inter-observer agreement for final PI-RADS classification 
between both radiologists was calculated using weighted kappa values. Gleason 
score (GS) ≥3+4 was assumed to be csPCa.
Results
Yield of repeat MRGB
During MRGB-2, 16 of 75 (21%) biopsied lesions resulted in csPCa. Of 63 rebiopsied 
lesions, 33 (52%) showed  PCa and 13 (21%) csPCa. Six lesions harbored GS 3+4, two 
GS 4+3, two GS 3+5, one GS 5+3 and two GS 4+5. The median volume of lesions with 
detected csPCa at repeat biopsy was 0.67ml (0.39-2.1) and the median increase in 
volume of these lesions was 0.43 ml (interquartile range [IQR], -0.080 – 0.70). 
Lesion location was represented in Table 2. 
In two patients, csPCa was detected (GS 4+5 and 3+5) at repeat biopsy, while the 
volume of the lesion decreased between MRGB-1 and MRGB-2. In both patients, 
two radiologists agreed on the accuracy of MRGB-1 hitting the lesion properly. 
Figure 2-5 are  examples of patients with csPCa findings at repeat biopsy.
Characteristics of positive lesions on MRGB-2
 At initial mpMRI, 32 lesions scored PI-RADS 2 after consulting the third reader. 
Five lesions scored PI-RADS 3. PI-RADS 4 was scored in 19 patients. The remaining 
7 patients scored PI-RADS 5 at initial mpMRI. Detection rates for csPCa was 19% 
(6/32) in PI-RADS 2, 20% (1/5) in PI-RADS 3, 11% (2/19) in PI-RADS 4 and 57% 
(4/7) in PI-RADS 5, respectively. Any PCa was detected in 41% (13/32), 80% (4/5), 
53% (10/19) and 86% (6/7) in PI-RADS 2, 3, 4 and 5, respectively
Table 2   Location of a lesion correlated to the detection of (clinically significant) 
prostate cancer
PZ TZ PZ/TZ Total
GS = 3+3 8 7 5 20
GS ≥ 3+4 7 5 1 13
No PCa 16 8 6 30
Total 31 20 12 63
GS = Gleason score; PCa = prostate cancer; PZ = peripheral zone; TZ = transition zone; PZ/TZ = lesions 
covering both the PZ and the TZ.
Figure 2   A 68 years old patient with a PSA of 9.9 ng/ml having an mpMRI-1  
and subsequent MRGB-1 of a lesion which was retrospectively scored 
PI-RADS 2 (A -D)
The maximal lesion diameter was 15 mm. After 11 months, his PSA increased to 12.6 ng/ml while the 
lesion volume decreased 0.23 ml. The maximum lesion diameter unchanged. At mpMRI-2, the lesion still 
scored PI-RADS 2 (E - H). During MRGB-2 (figure 3) a GS 3+5 csPCa was detected. A and E; axial T2 
weighted images, B and F; calculated axial ADC map, C and G; axial Diffusion Weighted Images, D and H; 
color map representing Dynamic Contrast Enhancement images.
PSA = prostate specific antigen; mpMRI = multiparametric magnetic resonance imaging; MRGB = 
magnetic resonance imaging guided biopsy; PI-RADS = Prostate Imaging - Reporting and Data System 
GS = Gleason score; csPCa = clinically significant prostate cancer
A
E
B
F
C
G
D
H
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Figure 3   Confirmation scan of the biopsy needle during MRGB of the patient 
represented in figure 2
A and B are respectively axial and sagittal images of MRGB-1. C and D are respectively axial and sagittal 
images of MRGB-2. The needle was assumed to properly sample the lesion. MRGB = magnetic resonance 
imaging guided biopsy
Figure 4   A 52 years old patient with a PSA of 3.0 ng/ml having an mpMRI-1  
and subsequent MRGB-1 of a lesion which was retrospectively scored 
PI-RADS 3 (A - D)
The maximal lesion diameter was 9 mm. After 17 months, his PSA increased to 8.6 ng/ml and the lesion 
volume increased 0.44 ml. The maximal lesion diameter increased to 13.5 mm. At mpMRI-2, the lesion 
scored PI-RADS 4 (E - H). During MRGB-2 (figure 5) GS 3+4 csPCa was detected. A A and E; axial T2 
weighted images, B and F; calculated axial ADC map, C and G; axial Diffusion Weighted Images, D and H; 
color map representing Dynamic Contrast Enhancement images. PSA = prostate specific antigen; mpMRI 
= multiparametric magnetic resonance imaging; MRGB = magnetic resonance imaging guided biopsy; 
PI-RADS = Prostate Imaging - Reporting and Data System GS = Gleason score; csPCa = clinically significant 
prostate cancer
Figure 5   Confirmation scan of the biopsy needle during MRGB of the patient 
represented in figure 4
A and B are respectively axial and sagittal images of MRGB-1. C and D are respectively axial and sagittal 
images of MRGB-2. The needle was assumed to properly sample the lesion. MRGB = magnetic resonance 
imaging guided biopsy
Figure 6   Detection of csPCa correlated to the time between MRGB-1 and MRGB-2 
and to the change in PSA
The triangles are representing the lesions with csPCa at MRGB-2 and the diamonds the lesions without 
csPCa at MRGB-2. PSA = prostate specific antigen; MRGB = magnetic resonance imaging guided biopsy; 
csPCa= clinically significant prostate cancer
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of our study allows us to raise the question whether our findings still apply in 
today’s practice. Therefore we reevaluated all biopsied lesions and we demonstrated 
that csPCa detection did not evidently change the course of the years in patients 
with repeat biopsy. 
 In retrospect, almost half of our cohort scored PI-RADS 2. This might be caused 
by an increase in experience we have in evaluating prostate MRI over the years. 
However, even within the cohort of patients with a reassessed PI-RADS 2, almost 
19% (n=6/32) harbored csPCa at repeat biopsy. This is remarkable, as a comparable 
csPCa detection rate was seen in this study in patients with PI-RADS ≥ 3 (23%, 
7/31). Moreover, detection rates for PI-RADS 4 and 5 described in the literature are 
quite higher. 17-20 This can have several causes, for example, the relatively small 
sample size of this study making a comparison of detection rates with those of 
other studies harder. Also, the lesions are already presampled making the yield of 
the rebiopsy poorer. Furthermore, involved radiologists may be biased by the 
knowledge that some of the biopsy results after MRGB-2 were positive for csPCa 
and that a first biopsy in the same lesion was negative. However, they were not 
aware of which and how many lesions were positive for csPCa. Also, the range of 
used mpMRI sequences might cause difficulties in the reassessment of the obtained 
images.
 Intriguing are the two lesions with a decrease in volume and yet csPCa at 
repeat biopsy, as these findings are contrary to one’s expectation. In both lesions, 
the radiologists rated the biopsies as accurate samplings of the lesions during 
MRGB-1. This can occur, for example, in case of surrounding tissue reaction which 
could be regressive in control scans and thus cause a false decrease in lesion 
diameter. 21 Further, we found that the time between MRGB-1 and MRGB-2 and PSA 
changes does not seems to influence the biopsy outcome of MRGB-2. Recommenda-
tions on timing of follow up in patients with change in PSA are therefore not 
possible. It appears that a rise in PSA, even a rapid increase in a relatively short 
period, seems not to be very helpful in selecting patients who will benefit from 
repeat biopsy. In an important amount of patients in our cohort with a rapid 
increase in PSA, csPCa was not detected during MRGB-2. On the other hand, none 
of the patients with a decreasing PSA had csPCa when resampling the same lesion. 
Also, timing of MRGB-1 does not seem to influence the results. The total number of 
performed MRGB-1 was highest in years 2010 and 2011, and also MRGB-1 of lesions 
resulting in csPCa at MRGB-2 was mostly performed within that time period. This 
might be explained by the fact that in our institution the total number of 
performed MRGBs was highest in that period.
 One explanation for the detection of csPCa during MRGB-2 after a first session 
was negative may be the limitation of the biopsy technique. Although confirmation 
scans are made with the biopsy needle left in position, it remains difficult to 
Discussion
To our knowledge, this study displayed  the results of the first cohort of patients 
having repeat MRGB with negative first biopsies collected in more than ten years. 
We demonstrated that it might be beneficial to repeat the MRGB in case there is a 
continuing suspicion for having csPCa,, despite a negative first MRGB, as csPCa is 
detected in 21% of 75 lesions biopsied at MRGB-2. With a csPCa detection rate of 
again 21% (n = 13/63) for resampling the exact same lesion, we also demonstrated 
that it might  be beneficial to target a lesion which was histologically proven to be 
negative on prior the MRGB.
 With increasingly performed targeted biopsies, urologists are more often 
faced with patients with a suspicious lesion detected on mpMRI and a negative 
pathology outcome for that suspicious lesion. Yet, there is no guideline for follow 
up in such patients. Our study demonstrated that it might be beneficial for some 
patients to undergo rebiopsy such a lesion. This underlines the importance of 
follow up for some patients.
 Studies about a repeat biopsy or surgery after MRI-TRUS fusion targeted biopsy 
show similar results. However, a head-to-head comparison is quite difficult due to 
the low number of patients in those and in our study. 12, 13 The lengthy time range 
Figure 7   Timing of MRGB-1 correlated to the number of lesions with csPCa 
detected during MRGB-2
In patients with repeat biopsy, MRGB-1 was never performed in 2016.
MRGB-1 = initial magnetic resonance imaging guided biopsy; csPCa= clinically significant prostate cancer
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the pathology should be evaluated carefully. Based on this study we cannot suggest 
which patients will benefit. Therefore, further study is warranted to establish 
predictors for a positive repeat targeted biopsy.
assess the intralesional needle placement. Second, it may be explained by the 
biological progression. However, with a median time between MRGB-1 and MRGB-2 
of 11 months in patients with positive MRGB-2, it is not very likely.
 The most important limitation of our study was the long time range in which 
we included patients. Unfortunately, it was necessary to include a reasonable 
amount of patients. In a period of more than ten years, there are only 62 patients 
who had a repeat MRGB after an initial negative MRGB in our hospital. Unfortunately, 
doubling our sample size would thus probably have taken another ten years. 
Apparently, urologists and patients are not inclined to have another MRGB after 
the first one was negative. This can be well explained by the additional patient 
burden, the costs and the lower probability to detect a csPCa at repeat biopsy. 
A limitation of this large time span is the introduction of a learning curve. 
Nowadays, we have a lot more experience in both mpMRI readings and targeted 
biopsiescompared to ten years ago. Several studies showed the importance of 
experience in prostate MR reading and the method of biopsy acquisition.7, 22 
To minimize this limitation, we reassessed all lesions according to PI-RADS version 
2. Also, we assessed whether the biopsy needle accurately targeted the suspicious 
lesion. Due to the small sample size, we were  not able to provide predictors for a 
positive repeat MRGB. Further, selection bias will be introduced in this study as we 
only chose resampled lesions. Included patients were  rebiopsied, because there 
was some reason to believe that patients had csPCa regardless of the negative 
findings during initial MRGB.
 Also, a recurring limitation of all biopsy accuracy studies is the lack of a gold 
standard, for example, transperineal template prostate mapping or final radical 
prostatectomy. It would be extremely interesting to know whether a negative 
biopsy outcome is truly negative. Also, we only performed targeted biopsy without 
an additional systematic biopsy. As some studies reported csPCa detection rates(up 
to 10%) using systematic biopsy, which would be missed in a targeted only 
approach. Some advocate to perform systematic biopsy in addition to targeted 
biopsy.1, 22, 23 Nonetheless, this study was only focusing on the yield of repeat 
targeted biopsy. It solely provides information on the utility of targeting a lesion 
again while it was negative for PCa on previous targeted biopsy. We hereby accept 
the chance that when we missed a lesion during the first biopsy, we might miss it 
again during repeat biopsy. In our institution, we try to minimize this chance by 
targeting each suspicious lesion at least twice. This approach, however, is debated 
as Schimmöller and colleagues demonstrated that there is limited benefit of 
targeting a lesion twice in the same session.24    
 Based on our results, taking the limitations into consideration, we can 
conclude that an important amount of patients might benefit from repeat biopsy 
after a negative MRGB. Disagreement between mpMRI lesion characteristics and 
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Introduction
Prostate cancer (PCa) is the most common malignancy among Western men and it 
is the second leading cause of cancer-related mortality.1 Measurement of serum 
prostate specific antigen (PSA) and a digital rectal exam (DRE) are the first steps 
in PCa diagnoses. The pathologic evaluation of 10-12 core systematic transrectal 
ultrasound (TRUS) guided biopsies of the prostate is the standard to confirm the 
diagnosis.2 Unfortunately, TRUS guided biopsy is prone to random and systematic 
error and it is associated with several problems, for example overdiagnosis of 
insignificant cancer and underdiagnosis of significant cancer.3  
 Recently, multiparametric (mp) Magnetic Resonance Imaging (MRI) has been 
introduced for the detection and localization of PCa. mpMRI allows for accurate 
assessment of the prostate and it can improve the diagnostic pathway of PCa. 
Despite the accurate assessment of mpMRI, pathologic confirmation of obtained 
biopsies remains the gold standard to finally objectify PCa and assess the 
aggressiveness. However, mpMRI can be used for direct in-bore or MRI-TRUS fusion 
guided biopsy. MRI-TRUS fusion guided biopsy can be divided into cognitive  and 
software assisted fusion. In the latter procedure the prostate is visualized in 
real-time using TRUS and the location of the tumor, annotated in the pre-biopsy 
mpMRI, is registered to these ultrasound images with the use of software. Both 
direct in-bore targeted biopsy studies and software assisted MRI-TRUS fusion 
biopsy studies have shown promising results in the detection of PCa.4-7 
 Software assisted MRI-TRUS fusion guided biopsy is less expensive and more 
readily available compared to direct in-bore biopsy and it is therefore most used to 
target suspected lesions seen on mpMRI. Software assisted MRI-TRUS fusion is 
offered by various commercially available platforms, each with its own specific 
features. The main difference between the platforms is the type of image 
registration being either rigid or non-rigid (elastic). Rigid image registration 
overlays the mpMRI images onto the TRUS images during the biopsy procedure 
without adjustment for possible deformation of the prostate due to patient 
movement or the introduction of the TRUS probe.8,9 Elastic registration on the 
other hand tries to compensate for this deformation and it is therefore expected 
that it would be more accurate than rigid image registration.10-12 The aim of this 
systematic review and meta-analysis is to compare the detection rates of clinically 
significant (cs)PCa between rigid MRI-TRUS fusion and elastic MRI-TRUS fusion.    
Abstract
Context  The main difference between the available Magnetic Resonance Imaging 
(MRI) – Transrectal Ultrasound (TRUS) fusion platforms for prostate biopsy is the 
method of image registration being either rigid or elastic. As elastic registration 
compensates for possible deformation, caused by the introduction of a ultrasound 
probe for example, it is expected that it would perform better than rigid registration.
Objective  The aim of this meta-analysis is to compare rigid with elastic registration 
by calculating for both subgroups the detection odds ratio (OR). The detection OR 
is defined as the ratio of the odds of detecting clinically significant prostate cancer 
(csPCa) by MRI-TRUS fusion biopsy compared to systematic TRUS biopsy. Secondary 
objectives were OR for any PCa and the OR after pooling both registration techniques. 
Evidence acquisition The electronic databases Pubmed, Embase and Cochrane were 
systematically searched for relevant studies according to the Preferred Reporting 
Items for Systematic Review and Meta-analysis Statement. Studies comparing 
MRI-TRUS fusion and systematic TRUS guided biopsies in the same patient were 
included. The quality assessment of included studies was performed using the 
Quality Assessment of Diagnostic Accuracy Studies version 2. 
Evidence synthesis Eleven papers describing elastic and ten describing rigid 
registration were included. Meta-analysis showed an OR of csPCa for elastic and 
rigid registration of 1.45 (95% CI, 1.21-1.73; p < 0.0001) and 1.40 (95% CI, 1.13-1.75; 
p = 0.002) respectively. No significant difference was seen between the subgroups 
(p = 0.83). Pooling subgroups resulted in a OR of 1.43 (95% CI, 1.25-1.63; 
p < 0.00001). 
 
Conclusions No significant difference is identified between rigid and elastic 
registration for MRI-TRUS fusion guided biopsy in the detection of csPCa while 
both techniques detect more csPCa than TRUS-guided biopsy.
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time interval used between mpMRI and biopsy, 2) Was targeted biopsy performed 
prior to systematic biopsy, 3) Underwent all patients the same biopsy procedure 
and 4) Were all patients included in the analysis. 
Data synthesis and analysis
We calculated the detection rates for each study of both csPCa and any PCa. To 
compare the elastic and rigid registration methods two subgroups were made. The 
detection rate was defined as the proportion of men in which (cs)PCa was detected 
divided by the number of men in the entire cohort.
 Detection odds ratios (OR) were calculated and compared using Review Manager 
(version 5.3).16 The OR is the ratio of the odds that (cs)PCa will be detected to the 
odds that it will not be detected with targeted biopsy compared to systematic 
biopsy. As we expect heterogeneity between the included studies a random-effects 
model was used. Significance of the overall OR and the OR of each subgroup was 
determined using a Z-test. To determine significant differences between the OR of 
the two subgroups a Chi2-test was used. To illustrate any heterogeneity of the results, 
the OR’s of the different studies are displayed using forest plots. The I2 statistic 
was used to quantify heterogeneity. An I2 below 40% indicates no substantial 
heterogeneity.         
Evidence synthesis
Literature search and study selection
Figure 1 shows an overview of the literature search and the study selection. The search 
yielded 8653 records, 6616 records left after removing duplicates. Based on screening 
title and abstract 45 articles remained. After removing articles using the same 
dataset and removing articles not fulfilling the inclusion criteria 19 relevant 
articles remained. One article was added after cross-reference searching which 
resulted in 20 included relevant articles. 
Study and patient characteristics
Supplementary table 1 summarizes the study, population, MRI and biopsy charac-
teristics of the included studies. Eleven papers using elastic image registration 
9,17-26 and ten papers using rigid image registration finally left.9,27-35 As one paper 
compared both techniques, it was included in both subgroups. The subgroup using 
elastic registration comprised 1598 men, the rigid registration subgroup 2318. 
In four studies the detection rate of csPCa could not be measured 24,29-31  and in 
one study the detection rate of any PCa could not be measured.18  
Evidence acquisition
Search strategy
The electronic databases Pubmed, Embase and Cochrane were systematically 
searched for relevant studies. No limitations on language or date were used. The 
following search term was used: (“magnetic resonance imaging” or “MRI” or “MR” 
or “NMR” or “mpMRI” or “ultrasonography” or “US” or “MR-TRUS” or ”MR-US” or 
“MR/US”) AND (“fusion” or “registration” or “targeted” or “target” or “software”) 
AND (“prostate” or “prostatecancer” or “prostatic neoplasm” or “PCA” or “cancer”) 
AND (“detection” or “rate” or “utility” or “yield” or “efficiency” or “results”). 
Reference lists and two recent review articles were searched for missed eligible 
articles.4,13 The last search was performed on July 7, 2015. All studies were imported 
into Endnote (version X7.2, Thomson Reuters). This study was performed according 
to the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guidelines.14
Study selection and data extraction
One reviewer (W.V.) performed the study selection and data extraction. A first eligibility 
assessment was performed based on title and abstract screening. The remaining 
articles were selected after full text assessment. Conference abstracts were not 
included. Only  studies comparing software assisted MRI-TRUS fusion and systematic 
TRUS guided biopsies in the same patient were included.
 The main outcome measure was the detection rate of csPCa. The definition of 
clinically significance elected in the original report was used in this review. 
So, different definitions of clinically significance were used. The secondary 
outcome measure was the detection rate of any PCa.
 A data extraction form was used to extract the following data: study, population, 
MRI and biopsy characteristics. The detection rates were calculated from the 
published data.  
Quality assessment
The quality assessment of the included studies was performed by two reviewers 
[W.V. and M. de R.] using the Quality Assessment of Diagnostic Accuracy Studies 
version 2 (QUADAS-2).15 Disagreements were resolved by consensus. The two 
reviewers were not blinded during this quality assessment. The signaling questions 
of domain 2 (Index Test(s)) and domain 4 (Flow and timing) were adjusted so that 
the quality assessment fit our research question. Domain 2 includes the signaling 
questions: 1) Is the systematic biopsy operator blinded for the location of the 
lesion found on mpMRI and 2) Was it clear at which threshold patients underwent 
targeted biopsy. Domain 4 includes the signaling questions: 1) Was an appropriate 
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Only one study used transperineal template saturation biopsy.32 The risk of bias 
regarding flow and timing was low in four studies.18,25,28,34 Five studies mentioned 
an appropriate time interval between MRI and the biopsy procedure.18,20,25,28,34 
Some studies performed a systematic biopsy prior to targeted biopsy.9,19,20,23,26,32   
Clinically significant prostate cancer
The detection rates for the individual studies are displayed in table 1. The OR for 
csPCa was 1.45 (95% CI, 1.21-1.73; p < 0.0001) and 1.40 (95% CI, 1.13-1.75; p = 0.002) 
for the elastic and the rigid registration subgroup respectively both in favor of 
targeted biopsy. No significant difference was seen between the subgroups (p = 0.83). 
Figure 3 shows a forest plot to illustrate heterogeneity. I2 was 9% for the elastic 
and 39%  for the rigid subgroup. 
 The median detection rate of csPCa in the elastic registration subgroup was 
34.59 (IQR, 20.30-43.97) and 25.34 (IQR, 14.29-36.05) for targeted and systematic 
biopsy respectively. The median detection rate of csPCa in the rigid registration 
subgroup was 25.19 (IQR, 22.58-35.74) and 23.13 (IQR, 12.16-28.52) for targeted and 
systematic biopsy respectively.
 Pooling both subgroups resulted in an OR of 1.43 (95% CI, 1.25-1.63; p < 0.00001) 
in favor of targeted biopsy with an I2 of 19%. The median for targeted biopsy 
was 25.96 (IQR, 21.44-43.25) and for systematic biopsy 25.00 (IQR, 14.06-29.90). 
The funnel plot depicted in supplementary figure 2 is symmetric so there appears 
to be no presence of publication bias.  
Quality assessment
The results of the quality assessment are depicted in figure 2 and supplementary 
figure 1. The risk of bias regarding patient selection was unclear in nine 
studies.18,20,28,29,31-35 The unclear risk was mainly caused by a lack of data on 
patient enrollment or patient exclusion. The risk of bias concerning the index test 
was low in three studies as these studies explicitly reported the operator of 
systematic biopsies was blinded for the target lesion.19,29,35 The concerns about 
applicability regarding the reference test scored high in all studies except for one 
as all studies used systematic TRUS guided biopsy as inadequate reference test. 
Figure 1   Chart showing the results of the literature search
8653Initial search
2037 removed duplicates 
Articles matchi ng search criteria 6616
45
6571 removed based on title and abstract  
Potentially relevant articles
19
26 removed:
- 6 double dataset
- 20 did not meet inclusion criteria 
F inal article selection 20
 1 added after reference searching 
1 article compared both techniques 
R elevant articles
Pubmed
2510
Cochrane
1144
E mbase
4999
E lastic
11
Rigid
10
Figure 2   Methodologic quality overview of risk of bias and concerns regarding 
applicability of the 20 studies included in this systematic review using 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
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Any prostate cancer
The OR of any PCa was 1.28 (95% CI, 0.97-1.71; p = 0.09) and 1.01 (95% CI, 0.80-1.27; 
p = 0.94) in the elastic and the rigid registration subgroup respectively both in 
favor of targeted biopsy. There is no significant difference between the subgroups 
(p = 0.19). Figure 4 shows a forest plot to illustrate heterogeneity. I2 was 69% and 
64% in the elastic and the rigid subgroup respectively.   
Supplementary figure 1  Methodologic quality assessment using Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) of each individual study
Figure 3   Forrest plots showing results of the meta-analysis of included studies 
reporting the detection rate of clinically significant prostate cancer (csPCa) 
detected by magnetic resonance imaging (MRI)- transrectal ultrasound 
(TRUS) fusion guided biopsy versus systematic TRUS guided biopsy
The squares indicate the mean, the whiskers indicate the 95% CI. The diamonds indicate the pooled 
estimate. M-H2 = Mantel- Haenszel method for random-effects.
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The median detection rate of PCa in the elastic registration subgroup was 43.46 
(IQR, 33.65-51.82) and 37.78 (IQR, 23.81-45.45) for targeted and systematic biopsy 
respectively. The median detection rate of any PCa in the rigid registration 
subgroup was 45.04 (IQR, 38.10-48.85) and 39.82 (IQR, 36.00-45.92) for targeted 
and systematic biopsy respectively. 
 Pooling both subgroups resulted in an OR of 1.13 (95% CI, 0.95-1.36; p = 0.17) 
in favor of targeted biopsy with an I2 of 67%. The median for targeted biopsy was 
43.83 (IQR, 35.16-50.34) and for systematic biopsy 39.82 (IQR, 34.24-45.86). The 
funnel plot depicted in supplementary figure 3 is symmetric so there appears to be 
no presence of publication bias.
Figure 4   Forrest plots showing results of the meta-analysis of included studies 
reporting the detection rate of any prostate cancer (PCa) detected by 
magnetic resonance imaging (MRI)- transrectal ultrasound (TRUS) 
fusion guided biopsy versus systematic TRUS guided biopsy
The squares indicate the mean, the whiskers indicate the 95% CI. The diamonds indicate the pooled 
estimate. M-H2 = Mantel- Haenszel method for random-effects.
Supplementary figure 2 Funnel plot for clinically significant prostate cancer
The circles indicate the studies regarding the rigid image registration and the squares indicate the 
studies regarding the elastic image registration.
Supplementary figure 3  Funnel plot for any prostate cancer
The circles indicate the studies regarding the rigid image registration and the squares indicate the 
studies regarding the elastic image registration.
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Supplementary table 1
Study Population MRI Biopsy
Author Design Patients  
used in 
analysis
Biopsy history Age (years) PSA (ng/ml) Prostate volume 
(cc) 
Magnetic 
field 
strength 
(T)
mpMRI 
Sequences
Endo-
rectal 
coil 
Score Biopsy 
threshold
Patients 
biopsied 
(%)
Fusion 
platform
(registration)
Route Standard 
test
Targeted 
biopsy 
first
No. of 
targeted 
cores per 
patient
Arsov  
et al., 2015
Prospective 1041 Prior negative biopsy Median 68 (IQR 
63-71)
Median 10.8
(IQR 7.4-15.5)
Median 60  
(IQR 42-82)
3 T2, DWI,DCE N 5-point and 
PI-RADS
Sumscore ≥ 10 
out of 15
104 (100) Urostation
(elastic)
TR TR 12-core Y Mean 5.4
Baco  
et al., 2015 
Prospective 861 Initial biopsy Median 64 (IQR 
58-69)
Median 6.9  
(IQR 5.2-9.2)
Median 45  
(IQR 33-60)
1.5 T2, DWI N 5-point ≥3 63 (73.3) Urostation
(elastic)
TR TR 12-core Y Median 2
de Gorski  
et al., 2015 
Prospective 232 Initial biopsy Mean 64
(SD ± 6.4)
Mean 6.5
(SD ± 1.8)
Mean 47
(SD ± 24.3)
1.5 T2, DWI, DCE N 5-point ≥2 232 (100) Urostation
(elastic)
TR TR 12-core N Median 2
Delongchamps 
et al., 2013 
Prospective 1332 Initial biopsy Mean 64.5  
(SD ± 7.9)
Mean 9
(SD ± 3.9)
Mean 58.3
( SD ± 28.6)
1.5 T2, DWI, DCE Y 3-point ≥2 82 (61.7) Urostation
(elastic)
TR TR
10-12 core
N Median 3
Fiard  
et al., 2013 
Prospective 30 Prior negative biopsy (17)
Initial biopsy (13)
Median 64  
(range 61-67)
Median 6.3  
(range 5.2-8.8)
Median 46  
(range 31-59)
3 T2, DWI, DCE N PI-RADS Sumscore ≥ 5 
out of 15
20 (66.7) Urostation
(elastic)
TR TR 12-core N Median 2
Mendhiratta  
et al., 2015 
Retrospective 370 Initial biopsy Mean 64.6  
(SD ± 8.5)
Mean 6.8
 (SD ± 0.3) 
Median  
(46 (IQR 36-62)
3 T2, DWI, DCE N 5-point ≥2 370 (100) Artemis
(elastic)
TR TR 12-core Y Mean 5.7
Meng  
et al., 2015 
Retrospective 1721 Prior negative Mean 65.9  
(SD ± 7.5)
Mean 8.9
(SD ± 0.7) 
Mean 76.9  
(SD ± 44.4)
3 T2, DWI, DCE N 5-point ≥2 172 (100) Artemis
(elastic)
TR TR 12-core Y N.A.
Peltier  
et al., 2015 
Prospective 110 Initial biopsy Median 65.8  
(IQR 59.5-70.7)
Median 6.9  
(IQR 4.6-9.6)
Median 44  
(IQR 35-59)
3 T2, DWI,DCE Y 3-point None 110 (100) Urostation
(elastic)
TR TR 12-core N Median 2.4
Portalez  
et al., 2012 
Prospective 129 Prior negative biopsy Mean 64.7  
(range 47-79)
Mean 9.6  
(range 2.7-40)
Mean 51.1  
(range 12-192)
1.5 T2, DWI, DCE Y 5-point N.A. 129 (100) Urostation
(elastic)
TR TR 12-core Y Mean 3.1
Sonn  
et al., 2013 
Prospective 94 Prior negative biopsy Median 65  
(IQR 59-70)
Median 7.5  
(IQR 5.0-11.2)
Median 58  
(IQR 39-82)
3 T2, DWI, DCE N 5-point ≥2 94 (100) Artemis
(elastic)
TR TR 12-core Y Mean 5.46
Ukimura  
et al., 2015 
Retrospective 127 Prior negative biopsy (70)
Initial biopsy (57)
Median 66  
(range 39-81)
Median 5.8  
(range 1.4-28.8)
N.A. 3 T2, DWI, DCE N 3-point ≥2 127 (100) Urostation
(elastic)
TR TR
10-12 core
N Mean  2.78
Borkowetz  
et al., 2014 
Retrospective 263 Prior negative biopsy (195)
Initial biopsy (68)
Median 66  
(range 47-83)
Median 8.3  
(range 0.4-86.6)
Median 50  
(range 12-220)
3 T2, DWI,DCE N PI-RADS ≥2 263 (100) Biojet
(rigid)
TP TR 12-core Y Mean 8.9
Brock  
et al., 2015 
Prospective 121 Prior negative biopsy Mean 64  
(SD ± 6.6)
Mean 11.7  
(SD ± 7.0)
Mean 64.6  
(SD ± 32.1)
3 T2,DWI, DCE N PI-RADS N.A. 114 (94.2) HI-VISION
(rigid)
TR TR 12-core Y Mean 2.8
Delongchamps  
et al., 2013 
Prospective 1312 Initial biopsy Mean 64.6  
(SD ± 6.7)
Mean 8.3
(SD ± 4.1)
Mean 55.7
(SD ± 35.1)
1.5 T2, DWI, DCE Y 3-point ≥2 78 (59.5) Esaote
(rigid)
TR TR
10-12 core
N Median 4
Junker  
et al., 2015
Prospective 50 Mixed  (no. N.A.) Mean 63.7  
(SD ± 7.9)
Mean 7.6
(SD ± 4.2)
Mean 49.2
(SD ± 21.9)
3 T2, DWI. DCE N PI-RADS ≥3 50 (100) Logic
(rigid)
TR TR 10-core Y Mean 4.5
Maxeiner  
et al., 2015 
Prospective 169 Prior negative biopsy (151)  
Initial biopsy (18)
Mean 65.6  
(SD ± 7.71)
Mean 13.9  
(SD ± 13.7)
Mean 60.6  
(SD ± 35.3)
3 T2, DWI N PI-RADS N.A. 169 (100) Aplio 500
(rigid)
TR TR 10-core Y Mean 1.86
Miyagawa  
et al., 2010 
Prospective 85 Prior negative biopsy Median 69
(range 50-84)
Median 9.9
(range 4.0-34.2)
Median 37.2
(range 18-141)
1.5 T2, DWI, DCE N N.A. N.A. 85 (100) RVS
(rigid)
TR Combined TP 
and TR 10-11 
cores
Y Mean 2.3
Radtke  
et al., 2015 
Prospective 294 Prior negative biopsy (108)
Initial biopsy (186)
Median 64
(IQR 60-71)
Mean 7.3
(SD ± 6.0) 
Mean 47
(SD ± 37.5)
3 T2, DWI, DCE N PI-RADS ≥2 196 (66.7) BiopSee
(rigid)
TP TP template 
saturation 
biopsy
(24-core)
N Median 4
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The results of our review are in line with other studies showing that software 
assisted MRI-TRUS fusion guided biopsy detects more csPCa without increasing 
the detection of insignificant PCa.4,34 The best biopsy strategy for PCa would only 
detect csPCa and no clinically insignificant PCa. The crux however is the definition 
of csPCa as no uniform definition exists.44,45 The included studies in this review 
used seven different definitions of csPCa, with Gleason score ≥ 3+4 being most 
used. Furthermore, almost all included studies applied the same definition for csPCa 
for both targeted and systematic biopsy. The definitions of clinically significance 
however are based on systematic TRUS guided biopsy instead of targeted biopsy. 
As targeted biopsy obtains a few cores from an identified lesion on mpMRI which 
is likely to be PCa, it is much easier for targeted biopsy to fulfill the criteria for 
clinically significance compared to systematic TRUS biopsy. Ideally whole-mount 
sections of prostatectomy would be used as reference to draw the conclusion that 
targeted biopsy would detect more csPCa than systematic TRUS guided biopsy.
A difference in accuracy between direct in-bore biopsy and MRI-TRUS fusion is 
not yet demonstrated. Arsov et al.17 concluded after a prospective randomized 
controlled trial that MRI-TRUS fusion combined with systematic TRUS-guided 
biopsy did not improve the PCa detection rate compared to direct in-bore guided 
biopsy in patients with at least one previously negative TRUS guided biopsy. To our 
Discussion
This systematic review did not identify significant differences in the detection 
rates of both any and csPCa between elastic image registration and rigid image 
registration for MRI-TRUS fusion guided biopsy while MRI-TRUS fusion guided 
biopsy as a whole detects more csPCa compared to TRUS guided biopsy. The results 
for any PCa did not differ between MRI-TRUS fusion and TRUS guided biopsy.
 These findings can be explained by the fact that rigid registration requires a 
cognitive optimization of the registration; after rigid software assisted fusion the 
operator compensates cognitively for any prostate deformation.  
The role of mpMRI in detecting and assessing aggressiveness of a tumor is increasingly 
being recognized and implemented in daily practice.36-38 As a consequence 
MRI-targeted biopsies are more and more being performed, both direct in-bore as 
MRI-TRUS fusion guided biopsy. Many studies reported higher or similar rates of 
csPCa detection whilst lower rates of clinically insignificant PCa were detected 
with MRI-targeted biopsy compared to TRUS guided biopsy.7,39,40 Results of 
cognitive fusion studies are contrasting, as some studies show superior and others 
show inferior detection rates compared to TRUS guided biopsy, though, software 
assisted fusion seems not to be superior to cognitive fusion.41-43
Supplementary table 1  Continued
Study Population MRI Biopsy
Author Design Patients  
used in 
analysis
Biopsy history Age (years) PSA (ng/ml) Prostate volume 
(cc) 
Magnetic 
field 
strength 
(T)
mpMRI 
Sequences
Endo-
rectal 
coil 
Score Biopsy 
threshold
Patients 
biopsied 
(%)
Fusion 
platform
(registration)
Route Standard 
test
Targeted 
biopsy 
first
No. of 
targeted 
cores per 
patient
Salami  
et al., 2015 
Prospective 140 Prior negative biopsy Median
 A) 66.3  
(IQR 61-72.8)
B) 65.3  
(IQR 60.3-68.2)3 
Median
A) 10.7  
(IQR 6.9-16.5)
B) 8.0  
(IQR 5.4-11.2)2 
Median
A) 46.5  
(IQR 35-61.6)
B) 56  
(IQR 40-70.8)2
3 T2, DWI, DCE Y 5-point ≥2 140 (100) Uronav
(rigid)4
TR TR 12-core Y 2
Siddiqui  
et al., 2015 
Prospective 1003 Prior negative biopsy (807)  
Initial biopsy (196)
Mean 62.1
(SD ± 7.5)
Median 6.7  
(IQR 4.4-10.7)
Median 49
(IQR 36-71)
3 T2,DWI, DCE,
Spectroscopy
Y 3-point None 1003 (100) Uronav
(rigid)4
TR TR 12-core Y Mean 5.3
Zhang  
et al., 2015 
Prospective 62 Initial biopsy Mean 68.4 (range 
51-79)
Mean 10.2  
(range 4.5-30.1)
Mean 34.1  
(range 19-64)
3 T2, DWI,DCE N PI-RADS ≥2 62 (100) RVS
(rigid)
TP TP Y Mean 4.2
Characteristics of included studies. PSA = prostate specific antigen; mp = multiparametric; MRI = magnetic 
resonance imaging; T2 = T2-weighted imaging; DWI = diffusion weighted imaging; DCE = dynamic contrast 
enhancement; PI-RADS = Prostate Imaging Reporting and Data System; TR = transrectal; N = no; Y = yes. 
1 Patients included in this analysis were part of a wider study, only data relevant for this review was 
used. 2 The article both compared rigid and elastic image registration. 3 The article is dividing the 
cohort based on the final results in A) patients with clinically significant prostate cancer and B) 
patients with no PCa or indolent PCa. Uronav offers both a rigid and a elastic image registration option. 
In this paper the rigid image registration option was used.
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impossibility of estimating the rate of true negative results of prostate biopsy. 
Studies are using TRUS guided biopsy as a reference test. This test however lacks 
accuracy. Studies using prostatectomy as gold standard are also biased  as the 
study population consists of patients with PCa which needs surgery. As both 
analyzed subgroups suffer this limitation it will not affect the comparison between 
these subgroups. A last limitation might be the fact that the elastic image 
registration subgroup only exists of two different platforms while the rigid 
subgroup exists of eight different platforms.
 To conclude, we did not identify a significant difference between rigid and 
elastic image registration for MRI-TRUS fusion guided biopsy in the detection of 
csPCa while both MRI-TRUS fusion guided biopsy techniques detect more csPCa 
than TRUS-guided biopsy. However, to address the aim of this review more 
appropriately, a study that compares elastic and rigid image registration more 
directly will be needed. Hereby, heterogeneity between both groups can be 
excluded.
knowledge, a study comparing direct in-bore guided biopsy with MRI-TRUS fusion 
alone is not yet performed. The cost-effectiveness of both direct in-bore and fusion 
guided biopsy is not yet proven definitely as presented evidence regarding the 
cost-effectiveness is contradictory.46,47 Though, the procedure of MRI-TRUS fusion 
guided biopsy is less expensive, less time-consuming and more readily available 
than direct in-bore guided biopsy and therefore there might be an important role 
of MRI-TRUS fusion guided biopsy in the diagnostics of csPCa.
 MRI-TRUS fusion guided biopsy is offered by several commercially available 
fusion platforms. No clear advantage is demonstrated of one platform over 
another.13 One study was included in our review comparing the two software 
assisted image registration techniques.9 They found a difference in favor of elastic 
registration. Though, the difference was not significant. This systematic review 
did not identify such a difference As a result of this review, costs and usability 
should be directive in the choice whether to use elastic or rigid registration.    
 The most important strength of this study is that it is the first to investigate 
the difference between elastic and rigid image registration used for MRI-TRUS 
fusion guided biopsy. A second important strength of this study is the calculation 
of OR between the detection of PCa by targeted biopsy compared to systematic 
biopsy. Bias introduced by a higher prevalence of prostate cancer in one group over 
another is hereby tried to exclude. This can be seen by the higher median detection 
rate for targeted biopsy in the elastic image registration subgroup compared to the 
rigid registration subgroup. As the detection rate for TRUS guided biopsy is also 
higher for that subgroup the OR between both subgroups does not significantly 
differ. Not all bias however can be excluded. Also a strength of this review is its 
focus on only studies assessing detection rates of targeted biopsy and systematic 
biopsy both in the same patient, in this way we attempted to reduce heterogeneity 
between studies. However, many included studies lack to mention the awareness 
of the operator of TRUS-guided biopsy of the identified lesion on mpMRI. This 
resulted in a poor outcome of the quality assessment of included studies. As a 
result the detection rate for TRUS guided biopsy might be overestimated.   
 A major limitation of this study is the heterogeneity between the included 
studies. Different definitions of csPCa, biopsy thresholds, and mpMRI protocols 
and scoring systems were used. Furthermore, significant heterogeneity can be 
introduced as there is a variation in non-rigid registration. The platforms use 
different in-house developed software.  Also some heterogeneity is introduced as 
some patients had a TRUS biopsy before while others were biopsy naïve. More 
homogeneity can be achieved by using the START recommendations published by 
Moore et al.48 Another limitation is the exclusion in some studies of patients 
without a lesion seen on mpMRI. This results in a selection bias probably in favor 
of targeted biopsy. A recurrent limitation in prostate biopsy studies is the 
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Introduction
Much progress has been made in the diagnosis of clinically significant prostate 
cancer (csPCa) with a growing role for multiparametric magnetic resonance imaging 
(mpMRI) in the last years.1, 2 Despite expanding evidence on the superiority of 
mpMRI and targeted biopsy over 10-12 core transrectal ultrasound (TRUS) guided 
biopsy in the detection of csPCa, TRUS guided biopsy is still standard of care.3-5 
MpMRI is recommended if clinical suspicion of csPCa persists in spite of a negative 
TRUS guided prostate biopsy.5
 Advantages of mpMRI and targeted biopsy are clear; in several men biopsy can 
be avoided and fewer but more accurate cores can be obtained.6 However, a 
drawback could be the associated costs. Therefore, techniques have been explored 
such as MRI-TRUS fusion guided biopsy so that costs of direct in-bore targeted 
biopsy (MRGB) can be saved. MRI-TRUS fusion uses mpMRI images which are fused 
with real-time ultrasound images. Yet, the superiority of one targeted biopsy 
technique over the other is not established, however it is hypothesized that MRGB 
is more accurate compared to MRI-TRUS fusion guided biopsy.7 As MRI-TRUS fusion 
guided biopsy still requires mpMRI, the technique is more expensive compared to 
conventional TRUS guided biopsy.
 Although the procedure of targeted biopsy is more expensive, costs may be 
saved as less men will be over- and undertreated.8 As a consequence, saving costs 
related to the therapeutic consequences may outweigh the higher diagnostic costs. 
Also, survival and quality of life (QoL) are affected by an accurate diagnosis which 
will influence the cost-effectiveness of the different biopsy strategies. However, 
testing such hypotheses in reality can be complex. To overcome these challenges, 
decision models are used.
 Results of several decision models evaluating mpMRI and subsequent targeted 
biopsy are published already. 9-11 However, none of these studies evaluated the 
cost-effectiveness of MRGB, MRI-TRUS fusion guided biopsy and TRUS guided 
biopsy in one model. Therefore, our study is focusing on the difference in cost- 
effectiveness between the three approaches. 
Material and Methods
Population
The hypothetical population of this study consists of biopsy naïve patients with a 
suspicion of having csPCa based on an elevated serum PSA or abnormal digital 
rectal examination (DRE).
Abstract
Background  Three commonly used prostate biopsy approaches includes systematic 
transrectal ultrasound (TRUS), direct in-bore magnetic resonance imaging (MRGB) 
and MRI-TRUS fusion guided biopsy. The aim of this study was to calculate which 
strategy is most cost-effective.
Materials and Methods  A decision tree and Markov model were developed to compare 
cost-effectiveness. Literature review and expert opinion were used as input. 
A strategy was deemed cost-effective if the costs of gaining one quality-adjusted 
life year (incremental cost-effectiveness ratio) did not exceed the used willing-
ness-to-pay (WTP) threshold of €80.000. A base case analysis was performed to 
compare TRUS and MRI-TRUS fusion guided biopsy. Because of a lack of appropriate 
literature regarding the accuracy of MRGB, a threshold analysis for MRGB was 
performed. 
Results  The incremental cost-effectiveness ratio for MRI-TRUS fusion biopsy compared 
with transrectal ultrasound guided biposy is €1386 per quality adjusted life year 
gained, which was below the WTP threshold and thus assumed cost-effective. 
If MRI is positive in a patient with csPCa, the sensitivity of MRGB for csPCa has to 
be at least 89% for csPCa, assuming an equal accuracy to MRI-TRUS fusion biopsy 
for insignificant PCa. If that is the case, the ICER is €80 000 per QALY gained and 
thus cost-effective.
Conclusion  MRI-TRUS fusion seems to be cost-effective compared to TRUS guided 
biopsy. Future research is needed to provide evidence whether MRGB is the best 
pathway; in this study a threshold was calculated at which it would be cost-
effective.
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Decision model
A decision-analytic Markov model was developed to compare the cost-effectiveness 
of two new diagnostic pathways with the current standard of care for detecting 
csPCa. A decision tree was made to model the three diagnostic pathways and 
subsequent treatment options (supplementary figure 1). The current standard of 
care is to perform systematic TRUS guided biopsy in patients with a suspicion of 
having csPCa. The first strategy we compared with this standard of care was the 
MRI-TRUS fusion pathway. In this pathway, elevated PSA or abnormal DRE is 
followed by mpMRI. In case a suspicious lesion is seen on mpMRI, an MRI-TRUS 
fusion guided biopsy is performed. The second strategy was MRGB. Here, MRI-TRUS 
fusion guided biopsy is replaced by MRGB. After biopsy, three options were 
available for patients: prostatectomy, radiotherapy (RTx) and active surveillance 
(AS). As focal treatment is not yet standard of care, we did not include this 
treatment in our model. We assumed that in patients with a false-negative test 
(mpMRI or biopsy) eventually PCa would be detected and that in patients with a 
false-insignificant test (biopsy) eventually csPCa would be detected.12
A Markov model was used to represent the follow-up. The Markov model consisted 
of different health states in which patients moved according to a set of transition 
probabilities. The health states were: status after prostatectomy, status after RTx, 
status after AS and dead. After each cycle (one year) patients could either stay in 
their health state or die, depending on the probabilities of that state. Costs and 
utilities were appointed to each health state. The time horizon for this analysis 
was 18 years, as the study we used to abstract the survival data from had a 
follow-up of 18 years.13
 TreeAge Pro 2012 software (TreeAge Software Inc, Williamstown, MA, USA) 
was used for this analysis.               
Transition probabilities
An overview of the used transition probabilities can be found in table 1. We assumed 
that the specificity of all three biopsy techniques for any PCa was 100% as  a 
biopsy cannot be false positive. The remaining transition probabilities for TRUS 
guided biopsy and for MRI-TRUS fusion guided biopsy were subtracted from the 
“Comparison of Biopsy With Whole-Gland Pathology” data presented by Siddiqui et 
al.4 The transition probabilities for mpMRI were derived from Abd-Alazeez et al.14 
considering Gleason ≥ 3+4 being csPCa. The distribution in initial treatment was 
based on our institutional situation.
Table 1  Transition probabilities used in the decision tree
Parameter Value, % Source
Tumor prevalence
Tumor present when PSA is elevated (4-6 ng/
ml)
25 Kranse [2008]
Tumor significant when a tumor is present1 50 Expert opinion
Treatment options
Prostatectomy with csPCa1 70 Expert opinion3 
Radiotherapy with csPCa1 25 Expert opinion3
Prostatectomy with insignificant tumor1 40 Expert opinion3
Radiotherapy with insignificant tumor1 10 Expert opinion3
mpMRI
Sensitivity for csPCa1 93 Abd-Alazeez [2014]
Specificity for csPCa1 21 Abd-Alazeez [2014]
Specificity for any PCa 28 Abd-Alazeez [2014]
MRI-TRUS fusion 
Sensitivity for csPCa2 77 Siddiqui [2015]
False insignificant when mpMRI positive2 20 Siddiqui [2015]
Sensitivity for insignificant PCa2 50 Siddiqui [2015]
False significant when mpMRI positive2 32 Siddiqui [2015]
Specificity MRI-TRUS fusion guided biopsy 
any PCa
100 Expert opinion
TRUS
Sensitivity for csPCa 53 Siddiqui [2015]
False insignificant 34 Siddiqui [2015]
Sensitivity for insignificant PCa 55 Siddiqui [2015]
False significant 34 Siddiqui [2015]
Specificity TRUS any PCa 100 Expert opinion
MRGB
Specificity MRGB for any PCa 100 Expert opinion
1) csPCa is defined as Gleason score ≥ 3+4
2) csPCa is defined as GS ≥ high volume 3+4 (intermediate and high risk)
3) The distribution in initial treatment is based on our institutional situation.
PSA = prostate specific antigen; mpMRI = multiparametric magnetic resonance imaging; csPCa = clinically 
significant prostate cancer; TRUS = transrectal ultrasound; MRGB = direct in-bore magnetic resonance 
guided biopsy.
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procedures (0.8%)19, the costs of complications after biopsy are based on 5 days at 
the ward (€2365). The costs for AS and for follow up after the two treatment 
options were considered to be equal. Costs of AS consist of one consults of an 
urologists and the measurement of PSA per year. All future costs were discounted 
to their present value by a rate of 4% according to the Dutch pharmacoeconomic 
guidelines.20
Outcome measures
Effectiveness was measured by health-related quality of life (QALY). QALYs are 
adjusted life years corrected by the quality of those adjusted years. Utilities17 and 
survival data13, obtained after systematically reviewing the literature, are presented 
in table 3. Natural survival data were obtained from Statistics Netherlands (CBS).21 
According to the Dutch pharmacoeconomic guidelines, effects were discounted 
with a rate of 1.5%.20   
Data analysis
Mean costs, mean effects (in QALYs) and incremental cost-effectiveness ratios 
(ICERs) were calculated and compared between the strategies. ICERs are calculated 
by dividing the additional costs of a strategy by the additional QALYs as compared 
to another strategy. ICERs represent the additional costs to gain a QALY. The cost- 
effectiveness of a biopsy strategy is dependent on the willingness-to-pay (WTP) 
for one QALY. We used a WTP threshold of €80.000 (±£68.000 or $90.000) as 
recommended by the Dutch Council for Public Health and Care.22 So, a strategy is 
deemed cost-effective if the costs of gaining one QALY is €80.000,- or less. Which 
is higher, for example, than the WTP threshold recommended by United Kingdom’s 
National Institute for Health and Clinical Excellence (NICE) (£20.000 – 30.000; ± 
€24.000 – 36.000; $26.000 – 39.000).23  
 A base case analysis was performed between TRUS and MRI-TRUS fusion biopsy. 
Because of a lack of appropriate literature regarding the diagnostic accuracy of 
MRGB, a threshold analysis for MRGB was performed. We assumed an equal accuracy 
for both strategies for detecting insignificant PCa.
Cost information
Only health care costs were used in this cost analysis. Costs (€) were calculated 
according to the Dutch Methods for the economic evaluation of health care 
programs using costs information from the departments of Urology, Radiology, 
Radiotherapy and Pathology of our hospital.15 An overview of the cost data used 
in this analysis is presented in table 2. Costs for prostatectomy were calculated by 
the weighted mean of open and robot-assisted laparoscopic (RALP) approach (50% 
each). We calculated costs for 3 days at the ward after prostatectomy and included 
it in the unit costs. Costs of pathology were included in all biopsy techniques and 
in the prostatectomy procedure. Also, the costs for urine incontinence (€638)16 
in the first year after prostatectomy and RTx were included in the unit costs, 
corrected by the probability for developing it (11,5 and 0% for prostatectomy and 
RTx respectively).17 For the first year after RTx, costs for gastro-intestinal toxicity 
were included in the unit costs (Costs: €2545, probability: 7%).18 We assumed no 
difference in chance of developing complications after the different biopsy 
Table 2  Used cost data
Procedure Unit costs1, €
TRUS2 481
MRI-TRUS fusion
mpMRI 317
Biopsy2 481
MRGB
mpMRI 317
Biopsy 1095
Other costs
Radiotherapy 8686
Radical prostatectomy 9415
Active surveillance/follow-up 100
Urine incontinence after year 1 for Radiotherapy 13
Urine incontinence after year 1 for prostatectomy 26
TRUS = transrectal ultrasound; MRGB = direct in-bore magnetic resonance guided biopsy; mpMRI = multi-
parametric magnetic resonance imaging.  
1)  The costs of the different biopsy approaches includes purchase and maintenance. Also staff and 
material costs are included as is slot time (30 minutes for mpMRI, 60 for MRGB, 20 for TRUS and 20 
for MRI-TRUS fusion).   
2)  Costs of MRI-TRUS fusion biopsy and TRUS biopsy were considered the same as the difference in 
purchase of an ultrasound machine with or without a fusion option is negligible. The additional costs of 
a fusion option would be  around €3,-  (+/- € 8.000,-, a lifetime of 5-7 years, +/- 400 patients per year).
118 | Chapter 7 Cost-effectiveness of TRUS, MRGB and FGB | 119
Results
Cost-effectiveness of MRI-TRUS fusion compared to TRUS
According to our model, MRI-TRUS fusion is more effective compared to TRUS with 
an incremental effect of 0.13 QALYs. However, the latter procedure is less expensive 
with on average €2596 in costs per patient while the average costs of MRI-TRUS 
fusion per patient is €2771, which results in an incremental cost of €175 for 
MRI-TRUS fusion guided biopsy. As a result, the ICER for MRI-TRUS fusion guided 
biopsy is €1386 per QALY gained. As we assumed a WTP threshold of €80 0000, 
MRI-TRUS fusion is deemed cost-effective (table 4). Applying the threshold which 
is used by NICE, MRI-TRUS fusion would still be cost-effective.  
Threshold analysis for MRGB
MRGB would be cost-effective if the sensitivity for csPCa of MRGB is 11.8% higher 
than the sensitivity of MRI-TRUS fusion. So, if mpMRI is positive in a patient with 
csPCa, MRGB has to be true significant in at least 88.8% (77+11.8). If that is the 
case, the ICER is €80 000 per QALY gained and thus cost-effective (figure 1). In the 
hypothetical situation that the sensitivity of MRGB would be 100%, a gained QALY 
would cost €34 485 (ICER), this would just remain within the range recommended 
by NICE. The sensitivity of MRGB has to be 99% to be cost-effective, using the 
upper limit of the WTP threshold according to NICE. These calculations are based 
on the assumption that the sensitivity for insignificant PCa was the same for both 
biopsy techniques. Figure 2 is representing the results after varying this assumption. 
Deterministic sensitivity analyses
We calculated in our base case analysis that MRI-TRUS fusion is cost-effective 
compared to TRUS with an ICER of €1386. Ranging the assumptions based on expert 
opinion, cost or diagnostic accuracy parameters with realistic variations did not 
change this outcome. For example, the assumption that a tumor is clinically 
significant in 50% of the cases that a tumor is present has to be 5% or less, so that 
Table 3   Utilities and survival of different health states used in  
the Markov-model
Parameter Value, % Source
Utilities
Biopsy 99.4 Heijnsdijk [2012]
PCa diagnosis 98 Heijnsdijk [2012]
Prostatectomy 75 Heijnsdijk [2012]
Radiotherapy 77 Heijnsdijk [2012]
Active surveillance 97 Heijnsdijk [2012]
Post recovery 95 Heijnsdijk [2012]
Survival
Active surveillance for insignificant PCa 99.2 Bill-Axelson [2014]
Treated insignificant PCa 99.4 Bill-Axelson [2014]
Missed csPCa 97.4 Bill-Axelson [2014]
Treated csPCa 98.6 Bill-Axelson [2014]
Natural survival from the age of 65 (Year) Statistics Netherlands [2014]
1 98.85
2 98.7
3 98.52
4 98.31
5 98.18
6 98.02
7 97.82
8 97.63
9 97.31
10 97.06
11 96.66
12 96.22
13 95.85
14 95.17
15 94.47
16 93.91
17 93.03
18 92.32
csPCa = clinically significant prostate cancer
Table 4  Baseline results of TRUS and MRI-TRUS fusion.
Strategy Costs 
(€)
Effects 
(QALY)
Incremental 
costs (€)
Incremental 
effects (QALY)
ICER 
(€/QALY)
TRUS 2596 12.8162 x x x
MRI-TRUS fusion 2771 12.9425 175 0.1263 1386
TRUS = Transrectal ultrasound; MRI = magnetic resonance imaging; MRGB = direct in-bore magnetic 
resonance guided biopsy; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio. 
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the TRUS biopsy pathway would become cost-effective, i.e. an incidence of csPCa 
of 1%  in patients with raised PSA. Furthermore, the ICER of MRI-TRUS fusion 
would exceed the WTP threshold in case an mpMRI costs €9.500 or more per patient.
The cost-effectiveness of MRI-TRUS fusion biopsy would be even higher with an 
increasing specificity of mpMRI for csPCa. For instance, a specificity of 80% 
(instead of 21%) would result in an ICER of €470. Varying utilities did not 
significantly change the outcome of our base case analysis. The parameters which 
were most sensitive to change the base case analysis were survival after a treated 
csPCa and the survival with an untreated clinically insignificant PCa. When the 
yearly survival of a patient with a treated csPCa lowers from 98.6% to 93.2% TRUS 
biopsy would be the most cost-effective strategy. This would also be the case if 
survival of an untreated insignificant PCa would decrease from 99.2% to 96.5%.         
Figure 1   Incremental cost-effectiveness ratio (ICER) of direct in-bore magnetic 
resonance guided biopsy (MRGB)
On the x-axis the sensitivity of MRGB for clinically significant prostate cancer. On the y-axis the ICER 
in €/QALY. We assumed an equal accuracy for MRGB and MRI-TRUS fusion for detecting insignificant 
PCa. The dotted line is the willingness-to-pay (WTP) threshold of € 80.000. The ICER of MRGB is beneath 
the WTP threshold from an accuracy of 88.8%.
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Figure 2   Analysis of the cost-effectiveness of direct in-bore magnetic  
resonance imaging guided biopsy (MRGB) varying the sensitivity  
for significant prostate cancer (PCa) of MRGB plotted over the 
sensitivity for insignificant PCa of MRGB
On the x-axis the sensitivity of MRGB for significant tumors. On the y-axis the sensitivity of MRGB for 
insignificant tumors. The black line is representing the willingness-to-pay (WTP) threshold of € 80.000. 
To illustrate, the dotted lines indicate that in case the sensitivity for csPCa of MRGB is 81%, the sensitivity 
of MRGB for insignificant PCa has to be 67.5% to reach the WTP threshold and thus to be cost-effective.
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An important strength of our study is the use of recently published studies which 
covered the performance of mpMRI, TRUS and MRI-TRUS fusion guided biopsy. To 
avoid misleading conclusions around MRGB we performed a threshold analysis. 
Further, we extensively explored the effects of the parameters based on expert 
opinion with sensitivity analyses. Willis et al.10 concluded after a review of 
economic evaluations of diagnostic strategies for prostate cancer that the effect of 
difference in impact of prostate cancer and its treatment on the length and quality 
of life is rarely highlighted in studies regarding cost-effectiveness. Therefore, we 
also performed a comprehensive evaluation of the effect of the utilities and the 
survival.
Besides the strengths, we also have to discuss some potential limitations. The 
presented calculation is based on Dutch cost data. Therefore, it may be hard to 
extrapolate the model to other healthcare systems. We tried to overcome this 
limitation by presenting detailed input parameters. Hereby, the transferability of 
the results to another specific healthcare system can be assessed.26 In addition, we 
provided the WTP threshold recommended by NICE, which applies a threshold lower 
than the Dutch Council for Public Health and Care does. The cost-effectiveness of 
MRI-TRUS fusion would not be influenced by this lower WTP threshold. However, 
lowering the threshold to the upper limit according to NICE, the sensitivity of 
MRGB for csPCa has to be 99% instead of 89% to be the most cost-effective approach. 
Another limitation is that it was inevitable to use parameters based on expert 
opinion. The parameters based on expert opinion are representing the actual 
situation in our hospital. Again, questions may rise about the generalisability to 
other countries. Though, sensitivity analyses showed that varying those 
assumptions with realistic variations did not change the outcome of the results. 
For example, the main parameter based on expert opinion is the assumption that 
a tumor is significant in 50% of the cases in which a tumor is present in men with 
raised PSA. However, varying this assumption with realistic values did not change 
the outcome of our analyses. Also, the distribution of treatments between patients 
was based on the experiences in our hospital. Again, varying this assumption did 
not affect the conclusion of our analyses. A last important assumption we have to 
address is the assumption that in patients with a false-negative test eventually 
PCa would be detected and that in patients with a false-insignificant test eventually 
csPCa would be detected. Due to its high false-negative rate and its high false-in-
significant rate, the TRUS biopsy approach benefit most as survival increases in 
that group due to this assumption. Another limitation to keep in mind is the fact 
that this evaluation largely depends on the results of the included studies. All 
included studies suffer from a lack of a reliable gold standard to evaluate the 
performance of mpMRI, TRUS and MRI-TRUS fusion. We obtained the biopsy data 
Discussion
The results presented in our paper indicate MRI-TRUS fusion to be cost-effective 
compared to TRUS guided biopsy. In case the sensitivity of MRGB for csPCa is at 
least 89%, MRGB is the most cost-effective strategy.
For several decades, healthcare expenditures has been growing rapidly. The rise in 
expenditures is based on multiple components with technological improvements, 
often used during the diagnostic process, playing an important role.24 Also 
prostate cancer related costs are generated for a considerable part during 
diagnosis.25 Our results suggest that, despite the fact that MRI-TRUS fusion guided 
biopsy increases the costs of the diagnostic process even more, MRI-TRUS fusion is 
the most cost-effective strategy as health benefits from an accurate diagnosis. In 
our hypothetical model, MRI-TRUS fusion and MRGB benefit from a high sensitivity 
of mpMRI and subsequently a high rate of true csPCa detection with biopsy and as 
a result, the targeted biopsy approaches increase survival as less patients are 
undertreated.
 As the difference in initial costs between MRI-TRUS fusion and MRGB is €614 
in favor of MRI-TRUS fusion, sensitivity of MRGB for significant disease has to be 
at least 89% to be the most cost-effective strategy. Previously, de Rooij et al.9 
developed a model to compare TRUS guided biopsy with MRGB. They suggested that 
MRGB is cost-effective assuming a sensitivity of MRGB of 90% for any PCa. Due to 
insufficient literature of MRGB accuracy data usable for our analysis, we decided 
to calculate a threshold for MRGB whereby using an important assumption could be 
avoided.
 If specificity of mpMRI would increase, the cost-effectiveness of both targeted 
biopsy approaches would be better. Now, 72% of patients without any tumor and 
79% of patients with an insignificant tumor wrongfully undergo biopsy and 
consequently make unnecessary costs and experience disutilities. Contradictory, a 
burden for targeted biopsy is the ability to sample the most aggressive part of a 
lesion seen on mpMRI. In 32% of the csPCa lesions detected with MRI-TRUS fusion 
guided biopsy, the lesion was downgraded after prostatectomy to insignificant 
PCa, thus incorrectly assessed as being significant4. As a consequence, additional 
costs are made and disutilities are experienced by falsely treating such patients. 
At this moment, definitions for clinically significance are based on studies using 
TRUS biopsy. As targeted biopsy is increasingly being practiced, new definitions 
should be used to overcome this paradoxical drawback.
126 | Chapter 7 Cost-effectiveness of TRUS, MRGB and FGB | 127
published by Siddiqui et al.4 A limitation of that study was that they excluded 
patients without a lesion seen on mpMRI. Therefore, accuracy of targeted biopsy 
might be overestimated. However, the negative predictive value of mpMRI is 
approximately 90%.27 Thus, it is unlikely that this limitation would have changed 
the outcome of our analysis. Furthermore, to confine the consequences of the 
limitations we used a conservative modeling approach. The choices we made 
favored the TRUS biopsy pathway instead of the pathway regarding the new 
technologies. As all decision models encounter difficulties to represent actual 
complex situations, our model is hereby complicated. The results depend on the 
used input parameters as well as the depth of the calculation. For example, in our 
hospital mpMRI, MRGB and MRI-TRUS fusion biopsy is offered on a general basis 
and we therefore did not take into account costs coming with the introduction of 
the new technologies. Further, the cost-effectiveness of MRI-TRUS fusion and 
MRGB both depend on a high quality MRI. Unfortunately, in many countries 
sufficient prostate MR-quality is not warranted.
Conclusion
Taking the limitations in consideration, MRI-TRUS fusion seems to be more 
cost-effective compared to TRUS guided biopsy in a Dutch healthcare setting. 
Future research is needed to provide evidence whether MRGB is cost-effective as 
we calculated a threshold from where MRGB would be cost-effective.  
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Discussion
mpMRI
As discussed in the introduction, the advantages of mpMRI and targeted biopsy are 
clear: in some men biopsy can be avoided and fewer but more accurate biopsy cores 
can be obtained. As the chance of developing complications after a prostate biopsy 
is almost 1%, avoiding biopsy will reduce patient burden substantially.1 With a 
known sensitivity of 93% (95% CI, 88-96) and a negative predictive value of 89% 
(95% CI, 83-94), men with negative mpMRI results might safely avoid biopsy.2 
Nowadays, several institutions worldwide are using mpMRI to detect or to rule out 
csPCa. In the introduction we discussed the lack of literature about which proportion 
of patients avoids biopsy in a daily clinical routine because of negative findings on 
mpMRI. In Chapter 2 we demonstrated that 59.4% of men had such negative mpMRI 
results and thus avoided unnecessary biopsy. These results are remarkably higher 
compared to findings by other research groups.2,3 Recently, the PROMIS trial and 
the PRECISION trial reported that approximately 30% of patients avoid biopsy by 
using mpMRI as triage test.4 An explanation may be that our institution is experienced 
in mpMRI of the prostate. This is probably the explanation of our results being 
higher compared to other presented results. Another explanation is that PI-RADS 
may be applied conservatively in the afore mentioned studies, so as not to miss 
any significant tumors. This may introduce a bias, which is not present in the 
routinely scored exams of our retrospective study. This is also seen in the relatively 
large group of patients with a PI-RADS 3 in those trials. Also, an explanation may 
be that in a part of our patients with a PI-RADS 1 or 2 lesion was false negative.
 The differences between our and other presented results underlines the 
importance of adequate training in prostate MRI so that in daily clinical practice 
high sensitivities and negative predictive values can be obtained. If that can be 
achieved, then almost 60% of men can safely avoid biopsy according to our 
findings. The major challenge now is to take care every institute implementing 
mpMRI achieves acceptable sensitivities and specificities. The skills required for 
obtaining images with a good quality and the skills required for reading and 
interpreting are quite hard to train. Therefore, there are continued attempts to 
educate and train readers to provide uniform results worldwide. 
 In Chapter 3 we showed that in patients with mpMRI lesions classified PI-RADS 
3, 4 or 5 csPCa were detected in 17%, 34% and 67% respectively with MRGB.5 
Similar detection rates are found by other research groups.2,6-9  These numbers 
implicates that there is some work to do in order to increase the detection rates for 
csPCa, especially in PI-RADS 4 and 5. As PI-RADS 3 is reserved for those lesions 
which cannot be classified otherwise, the number of lesions scored PI-RADS 3 
should be as low as possible. PI-RADS version 2, published in 2016, supports 
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or lesions located ventrally or in the apex of the prostate or in patients with an 
PI-RADS (3), 4 or 5 and (repetitive) negative FGB sessions.
Negative targeted biopsy results
Of special interest for future studies are patients with positive findings on mpMRI 
and yet negative targeted biopsy findings. As targeted biopsy in mpMRI suspicious 
lesions is increasingly being practiced, urologists more often are faced with 
patients with a suspicious lesion detected on mpMRI but  a negative pathology 
outcome for that lesion. Previously, Chelluri et al. performed a study to determine 
the yield of repeated FGB of a same lesion in patients having a prior negative 
FGB.15 Repeated FGB in such lesions resulted in 6% csPCa detection. They concluded 
that negative FGB findings despite a positive mpMRI finding is a reliable finding. 
Though, our conclusion in Chapter 5 is the opposite. We reproduced their study, 
now repeating MRGB of a same lesion in patients having prior negative MRGB. The 
yield of csPCa in repeated MRGB was 21%. We thus concluded that patients might 
benefit from an MRGB in a positive mpMRI lesion despite a prior negative MRGB. As 
repeated MRGB is not regularly performed, we had to include all patients from 2006 
untill 2016. As a consequence, our sample size was quite small and this potentially 
limited our study. More literature, and prospectively collected data, is needed to 
determine the implication of a negative targeted biopsy finding (be it MRGB or 
FGB) despite a positive mpMRI finding. This is relevant as in this clinical scenario, 
patients are often intensively followed by measuring PSA, repeating mpMRI and 
even repeating targeted biopsy. During the data collection for some parts of this 
thesis, we encountered some patients who have had over 10 mpMRI sessions within 
the last 10 years. In future, we need to evaluate whether such an intensive follow 
up is needed.
 Another study that will be submitted for publication soon, in which we 
cooperated with a research group from Switzerland, evaluates the utility of MRGB 
in the same lesion with negative prior FGB despite positive mpMRI lesions. In 25% 
(n = 14/56) of such lesions, csPCa was detected with MRGB.
 Also, in Chapter 3 we performed an evaluation to investigate whether patients 
with negative biopsy findings yet positive mpMRI findings are being diagnosed 
with csPCa after our study period. With a median period of 41 months, this follow 
up was too short to make firm conclusions.
Role of ultrasound
As already mentioned, despite MRGB seems to be the most accurate targeted biopsy 
approach, FGB will have an important role in the diagnosis of csPCa in patients 
with positive mpMRI findings as it is a technique which is relatively simple 
and cheap to implement in a urologist’s practice. Several commercially available 
radiologists to avoid a PI-RADS 3 score as much as possible by upgrading a lesion 
to PI-RADS 4 in case DCE is positive in lesions in the peripheral zone of the prostate 
classified  PI-RADS 3 on DWI. Furthermore, lesions located in the transition zone 
classified PI-RADS 3 on T2-weighted imaging can be upgraded to PI-RADS 4 in case 
DWI is scored 5.10 In addition to this, we now demonstrated in Chapter 3 that 
lesions overall classified PI-RADS 3 can be downgraded by using the PSA density. 
In 0-9% of men with lesions scored PI-RADS 3 and a PSA density below 0.12 ng/ml/
ml csPCa is detected. This implies that a PI-RADS 3 lesion with a low PSA density 
can be downgraded to PI-RADS 2. As a consequence, such a patient avoids prostate 
biopsy. These findings are supported by findings presented by other research 
groups. For example, Hansen et al. showed a negative predictive value of 91% 
in patients with lesions scored PI-RADS 1 or 2 in combination with a PSA density 
below 0.1 ng/ml/ml. As a consequence, 8% of their study population could safely 
avoid biopsy.11 In our population, 26% of patients with a PI-RADS 3 could have 
been downgraded to a PI-RADS 2. This could be increased to 42% by using a PSA 
density threshold of 0.15 ng/ml/ml. With this threshold, in 2-15% of patients with 
PI-RADS 3, csPCa would then be missed. By additionally using a PSA density 
thresholds, patient burden and costs could be saved. However, we will then have 
to accept a small proportion of  false negatives.
MRI-targeted prostate biopsy
In Chapter 3 we demonstrated the results of MRI-targeted biopsy in patients with 
suspicious lesions. The used biopsy method was direct in-bore targeted (MRGB). 
This procedure, however, needs to be performed in a separate session because 
image post-processing and tumor detection and localization demand time. 
Therefore, the procedure is not readily implemented in daily clinical practice. The 
procedure is time consuming and it costs MRI “slot-time” which is scarce worldwide. 
Nonetheless, direct in-bore biopsy seems to be the most accurate way to target a 
suspicious mpMRI lesion.12 Although, in Chapter 4 we did not demonstrate significant 
differences between FGB and MRGB.13 Though, a major limitation of the study 
described in that chapter was the retrospective study design with a relatively 
small sample size. This is clearly illustrated by the wide range of 95% confidence 
intervals for FGB. This limitation could be a good explanation for the fact that we 
did not detect significant differences between both targeted biopsy methods. 
Unfortunately, there still is a great lack of literature addressing any differences in 
accuracy between different MRI-targeted biopsy methods.12,14 However, the 
question is whether relatively small differences between the MRI-targeted biopsy 
methods really matters. Given the limited availability of MRI “slot-time” it is not 
likely that MRGB will be widely accepted as primary targeted biopsy strategy. It is 
more likely that MRGB will be a solution in selected cases, for example small lesions 
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Cost-effectiveness
A frequently heard argument against mpMRI and targeted biopsy is the increased 
initial costs of the diagnostic work-up. However, according to different cost- 
effectiveness studies, a targeted biopsy approach using an mpMRI defined target 
might be cost-effective.21-23 In Chapter 7 we concluded that a targeted biopsy 
approach using FGB indeed seems to be beneficial.24 Although the initial costs of 
mpMRI and targeted biopsy exceed TRUS biopsy, mpMRI and targeted biopsy seems 
to be cost-effective as this last approach benefits health and quality of life; less 
men are under diagnosed so that an adequate treatment can be used. To test such 
hypothesis in reality is complex, therefore decision models are being used. Results 
from such studies, however, should be evaluated with caution. A major limitation 
is that all decision models encounter difficulties representing actual situations. 
Using a decision model forces you to make choices what to address and what not to 
address in your model. Also, during the design of the model, possibly not all 
situations are thought of. For example, a lot of patients with negative mpMRI 
findings are now often intensively followed by repeating PSA, mpMRI and 
sometimes even MRGB. This is a factor which is hard to implement in a decision 
model.  
Future directions
To place mpMRI and targeted biopsy in a more prominent role in the diagnostic 
process of men suspected for having csPCa, possibly the most important issue to 
address is the follow up after 1) negative mpMRI findings, 2) positive mpMRI 
findings but negative targeted biopsy findings and 3) positive mpMRI findings but 
insignificant PCa with targeted biopsy. As a consequence of our limited knowledge 
of the above mentioned issues, often patients are now intensively being followed. 
PSA is most used for follow up. However, in an important amount of patients, 
mpMRI is repeated multiple times and sometimes MRGB is even being repeated 
several times. 
 Also, the role of ultrasound in follow up is not yet appropriately addressed. 
Research is still being performed to optimize ultrasound. For example, the use of 
various ultrasound modalities are being investigated. In response to multipara-
metric MRI, some use the term multiparametric ultrasound (mpUS).25,26 A role for 
mpUS, maybe in the follow up of lesions localized with mpMRI, might further 
reduce costs.
   
Another important issue to address is the current definition of csPCa. In literature, 
different definitions are being used. Nowadays, most used is any Gleason score 3 + 
4 finding. Despite the several different definitions being used, they all have one 
thing in common: they do not apply targeted biopsy. Survival studies are needed 
platforms worldwide are now offering software to fuse mpMRI with TRUS. There 
are a lot of differences between the various platforms. For example, the use of 
tracking mechanism (mechanical arm or electromagnetic), biopsy route (transrectal 
or transperineal) or the way images are displayed (side-by-side or superimposed). 
The main difference between the platforms, however, is in the way of image 
registration: rigid or non-rigid (elastic). Rigid registration does not compensate 
for possible prostate deformation due to, for example, the introduction of an 
ultrasound probe while elastic image registration uses software to register the 
prostate deformation and artificially modifies the mpMRI images. Hereby, mpMRI 
data is stretched and distorted so that a reliable overlay is achieved.16 In Chapter 
6 we demonstrated that there is no significant difference between rigid and 
non-rigid image registration.17 A previously published study comparing the 
different fusion platforms also did not detect differences in detection rates for 
csPCa.18 Our results may be explained by the fact that rigid image registration 
requires a cognitive optimization after the image registration is done. Further, we 
confirmed findings by other research groups that FGB detects more csPCa compared 
to TRUS biopsy.2,8,12,19,20 As evidence is thickening about the superiority of mpMRI 
and targeted biopsy over TRUS biopsy we have to reevaluate the value of TRUS 
biopsy in the diagnostic process. Nowadays, most groups demonstrating superiority 
of MRI-targeted biopsy over TRUS biopsy conclude that a targeted approach might 
benefit patients with prior negative TRUS biopsy or they conclude that MRI-targeted 
biopsy may be beneficial as an additional approach next to TRUS biopsy. This is 
supported by csPCa detection with a TRUS biopsy approach in men with negative 
mpMRI findings or negative MRI-targeted biopsy results.2,8 Most authors nowadays 
propose a targeted biopsy approach in addition to systematic TRUS-biopsy. 
However, you might argue the relevance of csPCa detection by TRUS in cases 
without lesions seen on mpMRI. It is questionable whether such a finding does 
affect a men his life. Interesting is the way the PROMIS trial handles positive TRUS 
findings with negative findings on template biopsy. Their statistical analysis plan 
treated such findings as false positives.2 Nowadays, the definitions of csPCa are 
based on TRUS studies. With targeted biopsies performed, we should reevaluate 
whether old csPCa definitions are still relevant. With mpMRI and targeted biopsy 
now being performed, we are able to add mpMRI characteristics next to pathology 
characteristics to determine a lesion as being clinically significant, for example 
PSAD en ADC characteristics. In future, to omit TRUS biopsy will be one of the most 
important steps in PCa diagnostics, especially patients will be relieved to avoid 
TRUS biopsy. Hereto, we have to decrease the number of csPCa detected with TRUS 
while missed by mpMRI and/or subsequent MRI-targeted biopsy. Also, we probably 
have to accept a number of false negative findings in a targeted only approach.
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to determine the implication of biopsy findings using targeted biopsy. The 
implication of a Gleason score 3+4 detected by a targeted biopsy approach might 
be different from a same Gleason score detected by TRUS biopsy. Also, mpMRI 
should have a more important role in the determination of a lesion being csPCa. For 
example, lesion size and parameters such as PSA density, ADC values or enhancement 
patterns may be useful in the prediction of a lesion being csPCa or not. One or two 
biopsy samples from a lesion is probably not sufficient to predict whether a lesion 
will influence a men his life. Though, a downside for using lesion volume on mpMRI 
is the risk of both overestimation and underestimation of true tumor volume.27-29 
Nonetheless, we should evaluate its opportunities in long-term survival data. In 
my opinion mpMRI and targeted biopsy must have a more prominent role in 
nomograms as it probably improves csPCa prediction.
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Summary
The preceding chapters of this thesis addressed the role of MRI and MRI-targeted 
biopsy of the prostate. Both direct in-bore and MRI-TRUS fusion guided biopsy 
were addressed.
Approximately one out of six men will be diagnosed with PCa in his life. Luckily, 
most of those men will not die from the disease and their lives will not be affected. 
In some men, however, this will be the case; their lives will be affected or they will 
die from PCa. Those cancers are referred to as clinically significant PCa (csPCa).
 The current standard to detect csPCa is to obtain prostate tissue with systematic 
12-core transrectal ultrasound guided biopsy (TRUS biopsy). Unfortunately, this 
procedure has major drawbacks. Therefore, nowadays MRI and subsequent MRI- 
targeted biopsy is increasingly being practiced. Radiologists reading MRI of the 
prostate, will assign a lesion on a scale (PI-RADS scale) from 1 to 5. With a higher 
score, the chance of having csPCa is higher. After a lesion is detected and scored 
PI-RADS 3, 4 or 5, it will be biopsied. This can be done within the MRI scanner 
(MRGB) or after fusing MRI images with ultrasound images (FGB). 
 In chapter 2  we demonstrated the distribution of PI-RADS in a population of 
men having mpMRI within the last six years. In this chapter, evaluating mpMRI in 
4259 patients in our institution, it was shown that 59.4% could avoid prostate 
biopsy because there PI-RADS score was 1,2 or 3 with a prostate specific antigen 
blood level (PSA) density below 0.15 ng/ml/ml.
 Chapter 3 reports on the experience of MRGB in our institution. We retrospec-
tively included 1057 patients having MRGB in our institution. All included patients 
had a PI-RADS score ≥ 3. csPCa was detected in 17%, 34% and 67% in patients with 
PI-RADS 3, 4 or 5 respectively. We further demonstrated that PSA density could be 
used in patients with a PI-RADS 3 lesion to avoid biopsy. In case patients with a 
PI-RADS 3 lesion and a PSA density below 0.15 ng/ml/ml would not be biopsied, 
42% of those men avoids biopsy. In 2 – 15% of men avoiding biopsy, csPCa would 
have been missed.
 In chapter 4 we performed a comparison of csPCa detection rates between FGB 
and MRGB. We included 51 patients with FGB and 227 patients with MRGB. All 
patients had a history of at least one prior negative TRUS biopsy and lesions scored 
PI-RADS 4 or 5 with a lesion size of at least 8 mm. The detection rate of csPCa for 
FGB was 49% compared to 61% for MRGB. This difference did not significantly 
differ.
 Chapter 5 evaluated the yield of repeat MRGB after a first negative MRGB in 
a same lesion. Within a timeframe of ten years, 62 patients met the inclusion 
criteria. Together, they had 63 lesions which were resampled during second MRGB. 
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Two radiologists reassessed all MRI and MRGB images. In 21% of those lesions, 
csPCa was detected during repeat MRGB while first MRGB was negative for any PCa. 
In two patients, csPCa was detected at repeat biopsy while the volume of the 
lesion, determined on MRI, decreased. In none of the patients with a decreasing 
PSA between both MRGB sessions, csPCa was detected. Remarkable is the finding 
that 19% of lesions score PI-RADS 2 at first MRI proved to be csPCa after MRGB.
 In chapter 6 we performed a systematic review and meta-analysis to compare 
rigid and elastic image registration in FGB. After searching different electronic 
databases, 11 papers describing elastic and 10 papers describing rigid image 
registration were included for further analysis. The calculated odds ratio (OR) for 
detecting csPCa by using rigid image registration compared with TRUS biopsy was 
1.4, the OR was 1.45 for elastic image registration. This did not significantly differ 
while both image registration techniques detected significantly more csPCa 
compared to TRUS biopsy.
 Chapter 7 evaluated the cost-effectiveness of three approaches in the diagnostic 
work up of patients with a raised PSA level or a suspicious digital rectal examination. 
The aim of the study was to calculate whether TRUS biopsy, FGB or MRGB was the 
most cost-effective strategy. Therefore, a decision tree and Markov model was developed. 
Literature review and expert opinion was used as input for this model. Because of 
a lack of appropriate literature regarding the accuracy of MRGB, we performed a 
base case analysis to compare TRUS and FGB and we performed a threshold analysis 
for MRGB. The incremental cost effectiveness ratio for FGB compared with TRUS 
was €1386 per quality adjusted life year gained. This is below the willing-
ness-to-pay- threshold of €80.000 and thus cost-effective. The sensitivity of MRGB 
has to be at least 88.8% to be cost-effective.
 Finally, in chapter 8 the role of MRI and subsequent targeted biopsy, both 
MRGB and FGB, was discussed. The main conclusion is to increase MRI reading 
quality by training radiologists. Future research  is needed to determine the 
implication of negative MRI findings and negative biopsy findings as nowadays 
MRI and biopsy is repeated, this is probably unnecessary. Hereby, costs and 
patients discomfort can be avoided.
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Samenvatting
In dit proefschrift werd de rol van MRI en MRI geleide prostaat biopsie onderzocht 
voor de diagnose van prostaatkanker. Twee methoden van MRI geleide prostaat 
biopsie werden hierbij bestudeerd, direct in de MRI scanner afgenomen biopsie 
(MRGB) en biopsie met behulp van echografie waarop eerder gemaakte MRI beelden 
worden gefuseerd (FGB).
 Bij ongeveer 1 op de 6 mannen wordt in zijn leven prostaatkanker gediagnos-
ticeerd. Een klein gedeelte van de mannen met prostaatkanker zal aan de ziekte 
overlijden of gaat er in zijn leven last van hebben. Een dergelijke prostaatkanker 
noemen wij klinisch significante prostaatkanker (csPCa).
 De huidige manier om csPCa te detecteren, is door systematisch met behulp 
van een transrectale echografie 12 weefselbiopten te nemen (TRUS). Helaas zitten 
er grote nadelen aan deze procedure. Daarom wordt er tegenwoordig steeds meer 
gebruik gemaakt van MRI en MRI geleide biopsie. Radiologen die de MRI beelden 
van de prostaat beoordelen geven een score aan afwijkingen die zij detecteren. 
Deze score gaat van 1 tot 5 (PI-RADS score). Hoe hoger de score, hoe waarschijnlijker 
het is dat de afwijking csPCa betreft. Afwijkingen met een score van PI-RADS 3, 4 of 5 
worden over het algemeen gebiopteerd. Dit kan gedaan worden via MRGB of FGB.
 In hoofdstuk 2 werd de verdeling van de PI-RADS score gedemonstreerd in 
een populatie van mannen die de afgelopen zes jaar een MRI van de prostaat in 
ons ziekenhuis hebben gehad. In dit hoofdstuk, waarbij de MRI scans van 
4259 patiënten werden geëvalueerd, werd aangetoond dat 59.4% van de mannen 
prostaat biopsie konden voorkomen omdat hun PI-RADS score 1 of 2 was of een 
PI-RADS score van 3 met een prostaat specifiek antigeen (PSA) densiteit lager dan 
0.15 ng/ml/ml.  
 Hoofdstuk 3 beschrijft de ervaring in ons ziekenhuis met MRGB. We hebben 
retrospectief 1057 patiënten geïncludeerd. Alle patiënten hadden een PI-RADS 
score groter of gelijk aan 3. csPCa werd gedetecteerd bij 17%, 34% en 67% van de 
patiënten met respectievelijk een PI-RADS score van 3, 4 of 5.
 Verder werd gedemonstreerd dat de PSA densiteit gebruikt kon worden bij 
patiënten met een PI-RADS 3 score om biopsie te voorkomen. Als patiënten met een 
PI-RADS 3 en een PSA densiteit lager dan 0.15 ng/ml/ml geen biopsie ondergaan, 
hoeven 42% van de mannen met een PI-RADS 3 niet gebiopteerd te worden. Bij 
2-15% van die mannen zal helaas csPCa gemist worden.
 In hoofdstuk 4 werd een vergelijking gemaakt in de detectie van csPCa tussen 
FGB en MRGB. We includeerden 51 patienten die FGB hebben ondergaan en 227 patienten 
die MRGB hebben ondergaan. Alle patiënten hebben in het verleden één of meerdere 
TRUS biopsie sessies ondergaan die negatief waren voor csPCa. Alle patiënten hadden 
afwijkingen die met MRI gescoord werden als PI-RADS 4 of 5. De afmetingen van 
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vooral richten op de betekenis van negatieve bevindingen bij MRI of negatieve 
bevindingen bij MRI geleide biopsie. Nu wordt onderzoek vaak herhaald, vermoedelijk 
zonder dat dit relevant is. Hiermee worden onnodige kosten gemaakt en ervaren 
patiënten veel ongemak.
de afwijking waren minstens 8 mm. Bij FGB werd in 49% van de mannen csPCa 
ontdekt, bij MRGB was dit 61%. Dit verschil was niet statistisch significant.  
 Hoofdstuk 5 evalueerde de detectie van csPCa in afwijkingen waarbij een 
eerder verrichte MRGB negatief was voor csPCa. In een tijdsbestek van tien jaar 
werden 62 patiënten geïncludeerd. Samen hadden zij 63 afwijkingen die tweemaal 
werden gebiopteerd waarbij de eerste biopsie negatief was. Twee radiologen herbe-
oordeelden alle MRI beelden en de beelden van de MRGB. In 21% van de afwijkingen 
die opnieuw gebiopteerd werden, werd csPCa ontdekt. Bij twee patiënten nam de 
omvang van de afwijking op MRI af terwijl er wel csPCa werd ontdekt bij de tweede 
MRGB. Bij geen enkele patiënt met een dalende PSA bloedwaarde werd csPCa 
ontdekt bij herhaalde MRGB. Opmerkelijk is het feit dat bij 19% van de afwijkingen 
die PI-RADS 2 scoorden, csPCa werd ontdekt bij de tweede MRGB sessie. 
 In hoofdstuk 6 werd een systematische review en een meta-analyse verricht om 
rigide en elastische registratie te vergelijken bij FGB. Na verschillende elektronische 
databases te raadplegen werden 11 artikelen die elastische en 10 die rigide registratie 
toepasten, geïncludeerd. De berekende odds ratio (OR) voor het ontdekken van csPCa 
met rigide registratie vergeleken met TRUS biopsie was 1.4, de OR voor elastische 
registratie vergeleken met TRUS biopsie was 1.45. Dit verschil was niet statistisch 
significant. Beide registratie technieken detecteerden wel significant meer csPCa 
vergeleken met TRUS biopsie. 
 Hoofdstuk 7 evalueerde de kosten-effectiviteit van drie benaderingen om csPCa 
te detecteren bij mannen met een verhoogd PSA of een afwijkend rectaal toucher. 
Het doel van de studie was om de kosten-effectiviteit van TRUS biopsie, FGB en 
MRGB met elkaar te vergelijken.
 Hiervoor werd een besliskundig model gemaakt. Gepubliceerde literatuur en 
de mening van experts werden gebruikt als input gegevens voor het model. Omdat 
er weinig literatuur is die kon gebruikt worden voor de input van MRGB, werd er 
voor MRGB een drempelanalyse verricht.
 De verschillende strategieën zijn vergeleken op kosten, voor kwaliteit gecorrigeerde 
levensjaren (QALY’s) en incrementele kosteneffectiviteitsratio’s. De incrementele 
kosteneffectiviteitsratio laat zien wat het kost om een QALY te winnen ten opzichte 
van een andere strategie.
 De incrementele kosten effectiviteitsratio voor FGB vergeleken met TRUS was 
€1386 per QALY. Dit bedrag is lager dan de drempelwaarde van €80.000 die veel gebruikt 
wordt om te bepalen of een strategie kosten effectief is. 
 De sensitiviteit van MRGB moet 88.8% zijn om de meest optimale strategie te zijn.
 In Hoofdstuk 8  werd ten slotte bediscussieerd wat de rol van MRI en MRI geleide 
prostaat biopsie is in de diagnostiek van prostaatkanker. De belangrijkste conclusie 
is dat de kwaliteit van de beoordeling van prostaat MRI in alle ziekenhuizen 
verhoogd moet worden door middel van training. Toekomstig onderzoek moet zich 
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Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
 -  BROK course
 -  Endnote
 -  RIHS introduction course  for PhD candidates
 -  Introduction day Radboudumc
2015
2015
2015
2015
1,5
0,5
1,0
0,5
b) Seminars & lectures
 -  Radboud Research Rounds
 -   Center for medical imaging- North Easth Netherlands 
conference 
 
2015 
2015
1,0
0,25
c) Symposia & congresses
 -  European Society of Urologycal Imaging (poster, Milan)
 -  European Congres of Radiology (oral, Vienna)
 -  RSNA (oral, Chicago)
 -   Society of Computed Body tomography and MR  
(poster, Nashville)
 
2016 
2016 
2016 
2017
0,5
0,5
1,25
1,0
d) Other
TEACHING ACTIVITIES
e) Lecturing
 -   Invited speaker 10th International Symposium on  
Focal Therapy and Imaging in Prostate and Kidney Cancer
2018 0,75
f) Supervision of internships / other
 -   Supervision of research internship of two medical students 2016-2018 2,0
TOTAL 12,25
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Dankwoord
Als gebruikelijk, een woord van dank voor eenieder die op enigerlei wijze heeft 
bijgedragen aan de totstandkoming van dit proefschrift.* 
Jurgen Fütterer, allereerst wil ik jou bedanken voor het in mij gestelde vertrouwen. 
De vele serieuze momenten van mijn promotie, afgewisseld met nog meer niet- 
serieuze momenten hebben er de afgelopen tijd een leerzaam en bovenal leuke tijd 
van gemaakt. Je hebt me de vrijheid gegeven mijn promotie in te richten zoals 
ik het wilde en was er op de momenten dat het nodig was. Voor mij werkte dit 
uitstekend.
Jelle Barentsz, ook jou wil ik bedanken voor de afgelopen jaren. Jouw volharding 
en ideologie zijn zeer bewonderenswaardig.  
Michiel Sedelaar, veel heb ik gehad aan de momenten dat we samen hebben kunnen 
sparren over de klinische kant van de diagnostiek van prostaat kanker. Uiteindelijk zijn 
radiologen toch alleen maar met plaatjes bezig, en heb jij (meer dan wij) een patiënt 
voor ogen. Ter herinnering: ik heb nog wel een bak gerookte paling van je te goed.
Henkjan Huisman, bedankt voor de begeleiding afgelopen jaren. Door jouw kennis 
van de wetenschap en je technische achtergrond heb je een grote bijdrage kunnen 
leveren aan mijn promotie. 
Dear members of  the manuscript committee, thank you very much for your time 
and efforts in reviewing the manuscript.
Paranimfen Geert en Jorre, bedankt dat jullie tijdens de verdediging naast mij willen 
staan. Verderop komen jullie nog “uitvoeriger” aan bod.
Alle co-auteurs, onder andere door jullie bijdrage is het proefschrift geworden zoals 
het nu is. 
Onderzoekers van het interventieteam, Jan, Joyce, Kristian, Martijn, Martin, Thomas, 
Tim, Tip en natuurlijk Annemarijke 2.0. Dank voor jullie wetenschappelijke input 
gedurende het promotietraject. Natuurlijk nog meer dank voor de niet-weten-
schappelijke input tijdens het promotietraject.    
*  Aan dit dankwoord kunnen geen rechten worden ontleend. De auteur van dit proefschrift aanvaardt 
aansprakelijkheid voor schade als gevolg van onjuistheden in dit dankwoord noch voor schade als gevolg 
van onvolledigheden.
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Nog niet genoemde (prostaat MRI) radiologen, in het bijzonder Marloes van der 
Leest, Sjoerd Jenniskens en Roel Mus. Mede door jullie uitleg over het onderwerp 
heb ik mijn promotie kunnen afronden. Marloes, ook dank voor de hulp tijdens 
fusiebiopsie, ik heb ontzettend veel geleerd en af en toe hard gelachen.   
MRI- en echolaboranten, secretaresses en collega’s van het trialbureau, hartelijk dank 
voor jullie ondersteuning de afgelopen jaren. In het bijzonder Marijke, Manita, 
Solange en Sebastiaan.
Koos van der Velden, de gesprekken die ik met je heb gehad als mentor, hebben 
veel waarde gehad in het afronden van dit proefschrift. Veel dank hiervoor.
Stefan Steens en Emmanuel Mylanus, respectievelijk hoofd/hals radioloog en 
KNO-arts. De eerste stappen die ik in de wetenschap heb gezet waren onder jullie 
hoede. Jullie enthousiasme (en connecties) hebben er toe geleid dat ik aan dit 
promotietraject ben begonnen. Me dunkt dat de start van een promotietraject een 
absolute voorwaarde is voor de afronding ervan.
Jorre, Eline, Bart, Marion, Vincent, Marije en Paulien, de afgelopen jaren hebben 
we samen vele mooie momenten gedeeld. Ik noem: de strip in Albufeira, bowlen, 
viandellen eten en andere (toch minder culinaire) etentjes, borrels en uiteraard de 
vele (afdwingbare) successen in het casino. Ik houd mijn hart vast voor wat nog 
gaat komen.
Geert, Gerdien, Joske, Saïd en aanhang, helaas wonen we nu allemaal verspreid in 
het land en zien we elkaar daardoor weinig. Weet dat ik de nu schaarse momenten 
die we delen heel belangrijk vind. 
Pap en Mam, de wetenschap dat jullie altijd voor ons klaar staan, doet mij ontzettend 
goed. Dank voor alle steun de afgelopen decennia.
Lieve Paulien, na al die jaren artikelen schrijven nu dan toch een “writers block”. 
Op jouw dringend verzoek geen zoetsappig verhaal en vooral geen huwelijksaanzoek: 
Gewoon bedankt dan maar!  
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Wulphert Venderink is op 17 oktober 1988 geboren in Apeldoorn. Achtereenvolgens 
werden daar de peuterschool, de basisschool en ten slotte in 2007, aan het Christelijk 
Lyceum, het VWO met succes afgerond. Halverwege de opleiding geneeskunde werd 
de studie een jaar gepauzeerd om fulltime een bestuursfunctie te vervullen bij de 
studievereniging. Na dit korte intermezzo werd in 2015, met de afronding van zijn 
scriptie aan de Glasgow University in Schotland, de opleiding geneeskunde behaald 
(Radboud Universiteit). Twee jaar later werd de studie Nederlands recht aan de 
Radboud Universiteit afgerond. De scriptie voor de afstudeerrichting Straf- en 
Straf procesrecht beschreef de juridische aspecten van postmortale radiologie. 
Op 1 januari 2015 begon het werkende leven met de start van een promotietraject 
op de afdeling Radiologie en Nucleaire Geneeskunde van het Radboudumc te Nijmegen. 
Het resultaat hiervan heeft u (als het goed is) inmiddels gelezen. Op 1 januari 2017 
werd gestart met de opleiding tot radioloog op dezelfde afdeling.
 Na zes jaar samenwonen in Nijmegen en een latrelatie van een jaar, wonen 
Wulphert en Paulien weer samen, nu in Deventer.

